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An Analysis of Loopholes in the Pharmaceutical Supply Chain, and Methods for Improving 
Control of Counterfeit Drugs in Nigeria. 
By  
Ojima Precious Yakubu  
In Nigeria, the term counterfeit drug refers to drugs that have outlived their shelf life, 
mislabeled drugs, drugs kept under inappropriate temperatures, and drugs produced under 
unfavorable conditions. The supply of counterfeit drugs is an issue of great concern for the 
government, regulatory bodies, and industry professionals in Nigeria. Though policies and 
guidelines exist to control the supply, a significant amount of operating results have not been 
achieved yet. In Nigeria, the drug supply system needs to be carefully managed to safeguard 
the flow of genuine drugs throughout the supply chain. A high level of monitoring and 
evaluation must be enforced at all levels of the supply chain to ensure the activities of 
counterfeit drug peddlers are reduced as much as possible.  
 
The purpose of this research is to identify and analyze the current challenges which facilitate 
the loopholes in the pharmaceutical supply chain in Nigeria and propose methods that can 
reduce how counterfeit drugs enter the supply chain. This research aims to interact with 
distributors and pharmacists because they are directly involved in the supply chain and are 
important contact points before a drug reaches consumers.  
Response Rate: A total of 20 people were scheduled to be interviewed, 10 distributors, and 10 
pharmacists. A total of 13 participants responded to the interview, 7 pharmacists and 6 
distributors with two responding via text, recording a response rate of 65%  
The survey was distributed to a total of 370 participants. 70 pharmacists and 300 consumers. A 
total of 55 pharmacists responded to the survey and a total of 202 consumers responded to the 
survey giving a total of 257 responses. Hence, recording a response rate of 69.45%.  
 
The loopholes facilitating the infiltration of counterfeit drugs are that the number of 
unqualified workers in the supply chain is greater than the number of qualified workers, the 
presence of open markets, and poor implementation of laws. To control the supply of 
counterfeit drugs more consumer awareness needs to be done and industry experts need to 
familiarize themselves with more anti-counterfeit technologies and to exercise greater care in 
sourcing drugs.   
 
Key Words: Counterfeit Drugs, Supply Chain Management, Nigerian Pharmaceutical Distribution 
Channel, NAFDAC (National Drug Law Enforcement Agency), Anti-counterfeit technology, MAS 
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DEFINITIONS 
Patent Stores are an informal community- based providers of healthcare. These are stores 
handled by people without formal training in pharmacy. These store sale over the counter 
pharmaceutical drugs on a retail basis for profit. They dispense but do not prescribe.  
Generic Drugs are medication similar to existing branded drugs, they have the same dosage 




CHAPTER 1: INTRODUCTION  
1.1 OVERVIEW 
For every pharmaceutical supply chain, the priority is delivering safe, efficient, and quality 
products to the final users. The management of the supply chain has become more complex 
over time because most importantly it involves the life of human beings and requires the 
participation of an increasing range of stakeholders (Kapoor et al., 2018). Due to the number of 
risks encountered by the pharmaceutical companies, which are vital players in the supply chain, 
they struggle to ensure the quantity and quality of the drugs supplied arrives at the correct 
location safely (Kapoor et al., 2018).  
 
Upon the successful development and production of a drug, the manufacturer prepares the 
drug to further dispatch it for distribution to ensure it reaches the patients for use. Some 
companies are solely in charge of the drug distribution, while other companies are involved to a 
certain extent in the distribution and then outsource the remaining phase of the distribution 
(Kapoor et al., 2018). Unfortunately, somehow these drugs are compromised either at the point 
of repackaging or from open markets whereby leading to the supply of counterfeit drugs to the 
patients. A compromised supply chain is one-way counterfeit drugs are supplied, other ways 
are changing the label of an expired drug to the current date or using false or improper 
ingredients to produce a drug, amongst other forms in which counterfeit drugs exist. From 
studies, carried out by World Health Organization, International Federation of Pharmaceutical 
Manufacturers & Association counterfeit drugs have been a thing of concern for various 
countries in the world, some have made more progress than the others while others are still 
coming up with ways to control this threat (WHO, 2010). The author of this paper intends to 
analyze the loopholes in the supply chain and propose methods that can help to improve the 





1.1.1.  Overview of the Supply Chain 
In the pharmaceutical industry, the supply chain is comprised of all organizational, operational, 
and value-adding activities to help facilitate the safe delivery of drugs from the manufacturer to 
the consumer (Olson, 2020). It is the combination of major business processes across the supply 
chain to create value for stakeholders and patients.  According to the council of supply chain 
management professionals, supply chain management is the planning and management of all 
supply activities from sourcing to procurement, conversion, and all logistics activities (Kapoor et 
al., 2018). The distribution channel is a set of interdependent marketing institutions that 
facilitate the marketing activities involved in the movement of goods from the manufacturer to 
the final consumers. The distribution channel involves the manufacturer, the distributor, the 
retailer, and finally the consumer (Mohanta, 2014). According to an article written in “supply 
chain management global” the distributor is also known as the wholesaler (Mhugos, 2014). The 
role of the distributor is to connect the manufacturer to the consumers, the distributor reduces 
the response time and increases the reach of a product. A distributor has the opportunity to 
examine usage patterns and recommend substitute products in an event of scarcity and they 
reduce and manage the chance of risk in the distribution channel (Mohanta, 2014). Typically, 
after a drug is released, the major stakeholders involved in the supply chain are the regulatory 
bodies, government agencies, drug distributors, hospitals, clinics, pharmacy chains, and 
retailers. According to Kapoor et al, they stated that the pharmaceutical supply chain is a 
complex system, in the sense that, the same supply chain responsible for the distribution of 
prescription drugs, is the same supply chain used in the distribution of Over the Counter (OTC) 
medicines, and generics. This complexity contributes to the difficulty the pharmaceutical supply 





Figure 1:The Pharmaceutical Supply Chain (Kapoor et al., 2018) 
The pharmaceutical supply chain in Nigeria has improved over the years compared to its initial 
state many years ago, but despite all the reforms which have been put in place, there are still 
loopholes that enhance the distribution of counterfeit drugs. In a survey released by UNIDO 
(United Nations Industrial Development Organization) reviewing the pharmaceutical profile in 
Nigeria, they highlighted some threats affecting the Nigerian Pharmaceutical System (UNIDO, 
2011). These are the high level of poverty and how it directly affects the lack of purchasing 
power, which severely destabilizes the market for drugs produced within the country (UNIDO, 
2011). Furthermore, the presence of informal open markets selling drugs in unauthorized 
premises constitutes a threat to the genuine local industry. Also, the stigma of substandard 
health, highly affects the exportation of drugs produced in Nigeria, hence because of the high 
number of counterfeit cases reported in Nigeria countries like Ghana ban the exportation of 
certain drugs in the country. Finally, the presence of an uncontrolled and chaotic distribution 
system and parallel imports is another threat to the industry (UNIDO, 2011). Furthermore, the 
UNIDO article stated that the Nigerian supply chain is saturated with unregistered and 
untrained pharmacists who are actively involved in the supply of pharmaceuticals and using 
unregistered sites. In rural communities, they receive supply from patent stores and vendors in 
open marketplaces, coupled with the absence of health facilities, these factors also contribute 





Figure 2: Pharmaceutical Distribution System in Nigeria (UNIDO, 2011) 
Before any pharmaceutical product is distributed in Nigeria, they are procedures put in place, 
these steps are also known as the four essential functions in the Nigerian pharmaceutical 
sector. these procedures are Registration, Procurement, Inspection, and Distribution, they apply 
to both imported drugs and drugs produced within the country.  
• Registration: at this stage, the efficacy of the drug is tested to ensure it will be efficient 
and effective in treating the specific disease, this is the first stage of decision making in 
the pharmaceutical system. The registration process includes usage, labeling, 
marketing, warning, and prescription requirement of the drug. Drugs that do not pass 
through the registration process are termed counterfeit drugs (Garuba et al., 2009).  
• Procurement: This is an interface between the public system and the drug suppliers. 
This involves aggregate purchasing, public bidding, managing inventory, analysis of 
offers, proper allocation of resources, payments, receipt of purchased drugs, and 
quality control checks. The purpose of procurement in the system is to obtain the 




•  Inspection: this is the inspection of goods at ports of entry and manufacturing sites 
within the country. According to NAFDAC’s list of inspected international sites as of 
2019, the majority of imported drugs in Nigeria originate from India and China. The 
inspection of pharmaceutical companies comprises NAFDAC ensuring all establishments 
adhere to all Good Manufacturing Practices (GMP) from manufacturing, sales, storage, 
and distribution of drugs (Garuba et al., 2009).  
• Distribution: this is the allocation, transportation, and appropriate storage of drugs at 
all times. All medications have unique storage specifications, such as refrigerators. For 
safe delivery of drugs, all information concerning the drug must move throughout each 
step of the supply chain to control inventory and deliveries (Garuba et al., 2009). Two 
of the mega distributors, which are known as national distributors in Nigeria are 
Worldwide Commercial Ventures (WWCV) and Assene-Laborex, these distributors act 
as an intermediary between pharmaceutical companies and distributors.  
1.1.2.  Overview of Counterfeit Drugs in Nigeria  
In 1989, 150 children died due to a Paracetamol formulation error. Later, around April 1990, 
close to 100 infants died of kidney failure in the Central regions of Nigeria. As if that was not 
tragic enough, in that same year, in the Southwest of Nigeria, about 26 children experienced 
the same symptoms, with only 2 managing to survive (Peterson, 2014). After a thorough 
investigation, it was discovered that the OTC pain killers administered were manufactured 
under substandard conditions, and the drugs were mislabeled; as opposed to the propylene 
glycol mentioned on the pack, it was ethylene glycol which was used, which is known to be 
harmful to the kidney (Peterson, 2014). These are a few of the situations that led to the 
establishment of NAFDAC. NAFDAC (National Agency for Food and Drug Administration and 
Control) was established in 1993 to regulate the quality of all pharmaceutical products in 
Nigeria, ensure proper registration of drugs, lead port inspection to monitor drugs which are 
imported & exported in Nigeria and to investigate and ensure proper compliance with all 
regulatory requirements. NAFDAC which is a parastal under Federal Ministry of Health in 
Nigeria, works with other government parastal to ensure the proper enforcement of laws 




Authority), to investigate proper compliance with regulations they work with PCN (Pharmacist 
council of Nigeria) and other government parastatals to achieve their objectives (NAFDAC, 
2017).   
  
In Nigeria, the term counterfeit drug refers to drugs that have outlived their shelf life, 
mislabeled drugs, drugs kept under inappropriate temperatures, drugs not registered with 
National Agency for Food and Drug Administration and Control (NAFDAC), drug without 
complete manufacturer information and drugs produced under inconducive conditions. 
According to WHO (World Health Organization) and IFPMA (International Federation of 
Pharmaceutical Manufacturers & Association), counterfeit drugs are drugs whose identity, 
ingredients, or even origin are labeled falsely to deceive patients. False packaging, manipulated 
expiration dates, and incorrect direction of dosage are all patterns which counterfeit medicine 
exhibit (Robles R. et al., 2015). Also according to WHO, counterfeit drugs make up 25 percent of 
available drugs in developing countries, and 40 percent of the total supply in Nigeria - with 36.5 
percent of antimalarial drugs and antibiotics in the country being substandard (Morris and 
Stevens, 2006). Subsequently, since 2013, WHO has received reports of 1500 cases of 
counterfeits drugs, with WHO Africa making up 42% of the report, and WHO America and WHO 
Europe having 21% respectively. This reported percentage only includes the cases which could 
be recorded, meaning that a large chunk of counterfeit drug cases are still unaccounted for and 
are not reported (Bagozzi and Lindmeier, 2017). Based on the above statistics mentioned above 
by Bagozzi and Lindmeier, if a large number of counterfeit drugs are yet to be accounted for, in 
2013, this simply means that the life of patients is still largely at risk. 
 
According to Felix Gilette, He likened the investigation of counterfeit drugs to that of 
investigating a drug cartel, because as much as these drugs are easily seen in shops and sold 
online, the Kingpins are difficult to source out (Gillette, 2013). Counterfeit drugs are a lucrative 
business, in a year counterfeiters make roughly about 200 billion dollars, which makes it even 
more difficult to break this criminal practice (Millar, 2020).  To catch the distributors of these 




supply chain. One of the major contributors to the circulation of counterfeit drugs in Nigeria is 
the uncoordinated drug distribution system in Nigeria, which does not comply with the National 
Drug Policy. Unfortunately, attempts to minimize or eradicate the supply of counterfeit drugs 
do not make much progress, because Nigeria has an operative open drug market  (Ojo, 2017).  
 
The open drug market is unregulated and their locations are not a secret, but every attempt to 
shut them down has been futile because it is a situation of “they are aware they exist, but no 
concrete evidence to pull them down yet” and also because other merchandise are been sold 
within the same area. So hidden behind these other businesses are the counterfeit drug 
paddlers (Chinwendu, 2008). The notable open drug markets in Nigeria are Idumota Market in 
Lagos State, Sabon-Gari Market in Kano State, and Head-Bridge Market, Onitsha in Anambra 
State. Furthermore, Abiodun Raufu stated in an article for WHO, that every attempt to pull 
these markets down by taskforce has been unsuccessful (Raufu, 2006). Drugs are produced in 
these markets in unsterilized conditions and sold open air in corner stores, hawked on the 
roadside, and even alongside perishable items like vegetables (Fatokun, 2016).  
 
1.1.3.  Regulatory Bodies 
Across the world, every country has its particular regulatory authority which deals with the 
safety, efficiency, effectiveness, and quality of drugs. Despite the difference in location, 
language, and government operation the goal of these regulatory bodies are similar across 
borders. Some of the goals they have in common are to provide and implement pharmaceutical 
laws that control the research and development, product registration, pricing, manufacturing, 
and distribution, market, and protection of intellectual property. At the core of all these is to 
ensure the consumer is safe from any form of drug-associated hazard. In relation to this 
research, these are the regulatory bodies that control the distribution of drugs within Nigeria;  
 
Federal Ministry of Health (FMoH): this is the arm of the federal institutions in Nigeria, that is 
responsible for providing quality health services for Nigerians. This institution oversees the 




delivery of efficient, effective, affordable, and accessible health services (Federal Ministry of 
Health, 2020). 
 
NAFDAC (National Agency for Food and Drug Administration and Control): NAFDAC was 
established by Decree No. 15 of 1993 as amended by Decree No. 19 of 1999 and now the National Agency for 
Food and Drug Administration and Control Act Cap N1 Laws of the Federation of Nigeria (LFN) 2004. 
NAFDAC is a department under FMoH which was officially established in 1993 to (NAFDAC, 
2017);  
• Regulate and control the production, importation, exportation, distribution, publication, 
and sales of all regulated products which are drugs, medical devices, chemicals, food, 
and cosmetics.  
• Conduct all appropriate tests to ensure all regulated products are produced according to 
all required standards.  
• Inspect all production sites and ensure they compile with the quality assurance system. 
• Inspect all Drugs, food, etc. produced within the country and imported into the country 
and ensure they follow due registration process before any form of distribution or sales 
is authorized.  
NDLEA (National Drug Law Enforcement Agency): The establishment of the National Drug Law 
Enforcement Agency (NDLEA) by the promulgation of Decree Number 48 of 1989, now Act of 
Parliament is focused on destroying illicit drugs in Nigeria. They work with the NAFDAC officials 
at the borders to inspect regulated products coming into the country (NDLEA, 2018). 
 
PCN (Pharmacist Council of Nigeria): PCN is a Federal Government parastatal established by 
Act 91 of 1992 (Cap P17 LFN 2004) which is responsible for regulating and controlling 
pharmaceutical education, practice, and training in all aspects. It is responsible for the 
registration and licensing of pharmacists and pharmaceutical premises which includes 
manufacturing, importation, distribution, wholesale, hospital, and pharmacies). PCN is also in 
charge of issuing permits to pharmacy technicians, and license/registration of patent and 





NDP (National Drug Policy): NDP Nigeria was adopted and established in 1990 to control the 
inadequacies in drug availability, supply/distribution. The establishment of NDP was as a result 
of factors such inadequate funding of drug supply, high dependence on the supply of imported 
drugs, poor procurement practices, the poor performance of drug distributors, and 
involvement of unqualified persons in the procurement, distribution, and sales of drugs 
(Ogbonna et al., 2015).  
1.2 RESEARCH PURPOSE 
The purpose of this research is to identify and analyze the current challenges which facilitate 
the loopholes in the supply chain in Nigeria and propose methods that can reduce how 
counterfeit drugs enter the supply chain. This research aims to interact with distributors and 
pharmacists because they are directly involved in the supply chain and are important contacts 
before it gets to the consumers. The interaction with the distributors and pharmacists is to 
understand the challenges they face in sourcing genuine drugs; how existing laws can be 
effectively implemented and gather suggestions for how the complexity and chaos associated 
with the supply chain system can be solved. To clamp down the supply of these counterfeit 
drugs the source of theses counterfeit drugs must be properly investigated and cut off whereby 
reducing the source and manner by which counterfeit drugs enter the supply chain.  
Furthermore, the researcher will use questionnaires to gauge the awareness of consumers on 
current anti-counterfeit technologies and how open they are to use new technologies.  
The researcher will be taking conclusions and recommendations from other countries as to how 
they have managed the issue of the supply of counterfeit drugs. She intends to draw lessons 
from these countries and see how well they can fit into the current state of the Nigerian 









1.3 RESEARCH OBJECTIVES  
The purpose of this dissertation is to achieve these objectives; 
1. To study the pharmaceutical distribution system in Nigeria and the drivers that aid the 
infiltration of counterfeit drugs.  
2. To evaluate the challenges faced with implementing Pharmaceutical Distribution laws in 
Nigeria, and to assess the challenges posed by the open market which facilitate the 
distribution of counterfeit drugs. 
3. To look at supply chain reforms and recommend improvements that can facilitate 
control measures to minimize the distribution of counterfeit drugs in Nigeria. 
1.4 RESEARCH QUESTIONS  
1. What are the factors that challenge the effective implementation of Distribution Laws 
and Regulations in Nigeria, who is responsible for ensuring these laws are implemented? 
2. What reforms from other countries can be recommended to improve the 
pharmaceutical supply chain system in Nigeria and can consumer behavior help to 
minimize the spread of counterfeit drugs? 
3. What are the loopholes in the pharmaceutical distribution system in Nigeria that 
facilitate the infiltration of counterfeit drugs and what are the challenges faced with 
closing the open markets in Nigeria? 
1.5 STRUCTURE OF STUDY  
Using a quantitative approach (questionnaires/ surveys) and qualitative approach (phone or 
video interviews) these are the methods the researcher will use to source her primary data. The 
questioners will be administered to pharmacists and consumers. The phone interview will be 
done with the distributors and pharmacists. The pharmacist will participate both in the phone 
interview and the questioner because they are the “middlemen” which makes them the point 
of contact for both the distribution side and the consumer side.  
Furthermore, as mentioned above the implementation of policies to restrict the supply of the 
counterfeit drug has been poor, hence during this research, lessons from other countries that 
have successfully managed the situation will be used as a basis to also support this study. 




awareness of the depth of the impact of counterfeit drugs, and their readiness to participate in 
reducing the spread and their acceptance to new solutions.  
This study comprises of five chapters, which are the introduction, literature review, research 
methodology, finding & analysis, and recommendation & conclusion 
Chapter 1: This chapter provides a brief introduction to the research study; it outlines the 
research questions and objectives and gives a framework of the research.  
Chapter 2: This section examines available empirical data from relevant literature and 
publications on the research subject. Also, for better understanding, this chapter explores 
academic views on the research subject which influences the overall direction of the research 
methodology.  
Chapter 3: The researcher explains the research methodology employed in this study, which is a 
mixed-method a combination of quantitative and qualitative methods. The use of these 
methods is to get an insight into the perception of industry experts on this topic and also 
understand the level of acceptability of current technologies by consumers.  
Chapter 4: This section aims to analyze data gathered from the interview and questionnaire 
distributed. The interview was carried out via zoom and phone call with two groups of people, 
pharmaceutical distributors, and pharmacists. The interview was held to explore and examine 
the perspective of industry experts on the research study. Qualitative data gathered was 
analyzed using thematic analysis where patterns and topics are defined, analyzed, and 
interpreted. The questioner was distributed to consumers and pharmacists, the questioner for 
pharmacists was used to get basic information from a wider range of pharmacist and the 
questioner for consumers was used to gather information on the level of acceptability of 
current anti-counterfeit technology by consumers. Consumers were needed for this study 
because the researcher will propose areas of improvement from the data gathered from this 
particular sample size. To analyze the questionnaire the researcher used Microsoft Excel for 
statistical analysis and graphical representation.  
Chapter 5: In the concluding chapter, the research questions are answered from the data 
gathered and the primary data is compared with the secondary data. Recommendations for 




1.6 SIGNIFICANCE OF STUDY  
Counterfeit drugs are harmful to the consumer because they expose the consumer to a harmful 
substance and increase the risk of adverse reactions, side effects, and allergy reactions. From 
the current literature review, there is a gap in the study of the Nigerian pharmaceutical supply 
chain concerning the infiltration of counterfeit products. Previous studies have evaluated the 
storage of drugs for each stage of the supply chain and how improper storage of drugs can 
affect the quality of the pharmaceutical product. Also, previous studies have evaluated the 
challenges of laws implementation and how counterfeit drugs can be minimized but there is a 
gap in the study of how to reduce counterfeit drug infiltration into the legitimate 
pharmaceutical supply chain.  
This study is significant because it will reveal the existing point of counterfeit drug infiltration in 
the Nigerian Pharmaceutical supply chain and how it can be reduced. This study will be an 
informative tool for the citizens of Nigeria, the regulatory bodies and health experts and the 
suggestions will be an instructive or directive device for the regulatory bodies and health 
experts.   
1.8 CONCLUSION  
An understanding of the current loopholes in the pharmaceutical supply chain will help the 
researcher deduce if patients' responses can help reduce the spread of counterfeit drugs. 
Analyzing all present technologies in place, the researcher will also identify why current laws 
are not as effective as they are supposed to be and propose methods that can improve on the 
present solutions. This study will also weigh in on the current policies and guidelines, list 
reasons for lack of implementation, and propose possible areas of improvement in 










CHAPTER 2: LITERATURE REVIEW   
2.1 INTRODUCTION  
The pharmaceutical supply chain represents the channel through which drugs move from the 
manufacturer to the end-users in good condition and quality. It can further be described as the 
link between the laboratory and the marketplace. According to Tim K. Mackey et’ al, they 
described the legitimate supply chain as a “path which is regulated and licensed by the ministry 
of health, or regulatory bodies where patients can expect to obtain authentic products supplied 
through a controlled supply chain (Mackey et al., 2015).” Unfortunately, this definition is the 
opposite of what is facing the current supply chain of pharmaceutical products in Nigeria. The 
distribution of counterfeit drugs is illegal and uncontrolled supply chains such as open markets, 
illicit online stores, etc. have tampered with the integrity and safety of the global medicine 
supply chain. Also, Tim et’ al stated that with the proliferation of health care across the world, 
ensuring the safety and integrity of the medicine supply chain has turned out to be an onerous 
task (Mackey et al., 2015). Globally, the health system is tied to a “strong supply chain”, this is 
so because a broken supply chain can cripple the health care system, tamper with the integrity 
of the public health and undermine possible outcomes health-wise (Mackey et al., 2015).  
 
According to Walter G. Chambliss et al, the impact of counterfeit medication on the legitimate 
global pharmaceutical market has been estimated to reach 75 billion dollars and the profit 
margin is greater than illicit trafficking. They also stated that the distribution of counterfeit 
drugs has in the past, been done through complex global networks that have been traced to 
terrorists and organized crime affiliates (Chambliss et al., 2012). The threat of counterfeit drugs 
has posed multiple challenges which have been recognized on a global level, prompting WHO to 
raise awareness and coordinate international law enforcement efforts against this global 
concern (Mackey and Liang, 2011). According to research conducted by WHO, the majority of 
counterfeit drug production is done in Asia, though the prevalence of counterfeit drugs is felt 
worldwide. In 2009, Interpol made a seizure of 20 million pills in China and Southeast Asia, 34 
million pills in Europe, and millions of Dollars from counterfeit drugs in Egypt. Despite these 




global counterfeit drug market, which is estimated to be roughly 75 billion dollars in worldwide 
sales as of 2010 (Mackey and Liang, 2011). Counterfeit drugs and pharmaceutical markets have 
created an opportunity for criminals to engage in this profitable and patient-endangering 
business. The globalization of counterfeit drugs is controlled by highly sophisticated criminal 
networks that involve multiple routes of import and export across borders and free trade zones 
around the world, facilitating the introduction of counterfeit drugs into the legitimate and 
global supply chain (Mackey and Liang, 2011).  
 
As mentioned in the introduction, drugs that are not NAFDAC registered, expired drugs that 
were relabeled and resold, or without an active ingredient are all tagged counterfeit drugs. In a 
baseline study conducted by NAFDAC in 2001, 68% of drugs available in Nigeria are not duly 
registered by NAFDAC and Later in 2004 NAFDAC confirmed that 40-50% of drugs in Nigeria are 
counterfeited (Akunyili, 2010). The majority of drugs in Nigeria are imported from countries in 
Asia, which are mainly India and China. As of 2009, the 92 pharmaceutical companies in Nigeria 
produced only 30% of internal drug supply within the country, while the remaining 70% of 
drugs in the country are from an external supply. These imported drugs also play a part in 
facilitating the distribution of counterfeit drugs, between 2001 and 2005 the supply of drugs 
from 30 Indian and Chinese pharmaceutical companies and 1 Pakistan company was ban 
because after an investigation carried out by NAFDAC these companies were confirmed to be 
importing counterfeit drugs to Nigeria (Morris and Stevens, 2006). 
 
2.2 THE CURRENT STATE OF PHARMACEUTICAL DISTRIBUTION SYSTEM IN 
NIGERIA 
On a global level, Nigeria is seen as a developing country, thus the pharmaceutical supply chain 
in Nigeria is seen as inadequate as is the case with many developing countries. In Nigeria, the 
pharmaceutical supply chain is grossly affected by poor management, insufficient funding, and 
an inadequate number of qualified workers. These discrepancies have led to the scarcity of 
genuine drugs giving rise to the presence of counterfeits, which has led to avoidable deaths and 




counterfeit drugs in Nigeria is the uncoordinated drug distribution system in Nigeria, which 
does not comply with the National Drug Policy. Unfortunately, attempts to minimize or 
eradicate the supply of counterfeit drugs does not make much progress, because in Nigeria 
open drug markets are in operation. (Chinwendu, 2008). 
According to Chukwu et al, they stated that a good number of drugs in the market have been 
adjudged as substandard, fake and adulterated, where 30% of antimalaria and 17% of generic 
drugs are counterfeited. As mentioned earlier in the introduction by Kapoor et’ al the 
pharmaceutical supply chain involves several stakeholders. The Nigerian supply chain also uses 
this mode of pharmaceutical supply, but the drug distribution is further handled by “too” many 
stakeholders which have played a part in causing the chaotic and uncoordinated supply chain 
system. Major pharmaceutical companies use private logistics companies, while international 
development partners use courier companies, and private manufacturers and importers use a 
separate distribution channel (Chukwu et al., 2017). These numerous distribution channels 
have resulted in the expiration of drugs before reaching the patients, and the sales of 
counterfeit drugs in unregistered and unlicensed premises sold by unqualified persons.  
 
In a publication titled “Detecting Counterfeit Drugs through Mobile Authentication Service 
(MAS): Users Challenges in Edo South Senatorial District” the author highlights that the Nigerian 
government is committed to eradicating fake drugs as one of the ways of safeguarding the 
health system. This need is what lead to the formulation of National Drug Policy (NDP) in 1990. 
The objective of NDP is to ensure that all drugs in the National Drug Distribution System are 
effective, efficacious, have good quality, and are safe (Eronmhonsele, 2015). Also, to minimize 
the spread of counterfeit drugs, other government health agencies such as Pharmaceutical 
Society of Nigeria, Nigeria Association of General Practice Pharmacist, Nigeria Association of 
Industrial Pharmacist and Pharmaceutical Manufacturers Group of the Manufacturers 
Association in Nigeria have organized seminars and a national symposium on counterfeit drugs. 
NAFDAC has also engaged several information and communication technologies to drive its 
regulatory processes. These technologies include an established website where information on 




accessible (Eronmhonsele, 2015). NAFDAC also has a cooperate portal that makes 
communication of in-house information and collaborations easy and a Laboratory Information 
Management System (LIMS) to facilitate quality laboratory procedures and data processes, as 
well as E-clearance portal which allows for online electronic clearance of goods at the ports. In 
addition to easy the process of registration and ensure all drugs are duly registered NAFDAC 
also introduced the use of an Automated Product Administration and Monitoring Solution. All 
these are efforts implemented by NAFAC to eradicate the spread of counterfeit drugs in Nigeria 
(Eronmhonsele, 2015). 
 
In Nigeria, the public sector, procurement, and distribution of drugs are both centralized and 
decentralized, most medical drugs are procured and stored by individual health care 
institutions, while drugs which are high demand such HIV, anti-malaria and tuberculosis are 
centrally procured and distributed from the Federal Central Medical Store (CMS) (Justine and 
Ilomuanya, 2016). Nigeria is divided into six geo-political zones and 36 states, each state in each 
zone has its own Central Medical Store and procures and stores pharmaceutical products for 
their public facilities (Justine and Ilomuanya, 2016). The distribution for the pharmaceutical 
private sector is handled via pharmaceutical distributors, although NAFDAC highlighted that 
unlicensed distributors play a very significant role in drug distribution at this level of the supply 
chain (NAFDAC and Sproxil, 2015).  
2.3 CHALLENGES OF SAFEGUARDING THE PHARMACEUTICAL SUPPLY CHAIN  
According to the European Generic Medicines Association, the most vulnerable point where 
counterfeit pharmaceuticals penetrate the legitimate supply chain is at the secondary 
distribution point and re-packagers. The presence of the secondary distributor creates an 
additional layer for handing over which diminishes information visibility whereby creating the 
opportunity for the infiltration of counterfeits in the supply chain. These multiple steps of 
distribution which involve series of back and forth amongst distributors generate a more 
complex supply chain, hence counterfeiters take advantage of this distribution complication to 





According to studies carried out by Chambliss Walter, Carroll Wesley et’ al, a perfect loophole 
which counterfeiters exploit is the “high demand and low supply avenue”. This issue exists in 
the U.S, Europe, Nigeria, and other countries. In a study carried out by Chambliss Walter, 
Carroll et’ al on “the role of the pharmacist in preventing the distribution of counterfeit 
medications”, they described the low supply issue as a “perfect storm” because this is a 
situation where legitimate distributors are unable to meet the high demand of an expensive 
medication or unable to meet market needs. Counterfeiters take advantage of this and break 
into the supply chain because during these situations, there is a shortage of supply and 
pharmacists are in search of alternative suppliers. 
 
In a report released by “GAN Business Anti-corruption,” it reported that corruption has 
impacted the Nigerian Pharmaceutical system, this has caused a struggle to curtail the 
production and trafficking of substandard pharmaceuticals. Also, the report stated that bribery 
is common among Nigerian customs and ports authorities which makes it easy for smuggled 
goods to enter via the borders and seaports. In addition to bribery at ports, the import clearing 
procedure is difficult which makes the whole procedure poor (GAN Business Anti-corruption, 
2017). Corruption is not only associated with ports clearing authority, this report further stated 
that the issue of corruption is also common in the Nigerian procurement sector where up to 
one-third of companies are expected to pay bribes before been able to secure government 
contracts (GAN Business Anti-corruption, 2017).  
 
In a study titled the “Transparency in Nigeria's public pharmaceutical sector: perceptions from 
policymakers” the authors established that corruption is one of the reasons for the 
preponderance of counterfeit drugs in Nigeria, they also added inadequate legislation, poor 
enforcement of existing laws, un-skilled professionals in the pharmaceutical business, loose 
control system and high cost of drugs. The authors evaluated the level of transparency in the 
four essential functions (Registration, Procurement, Inspection, and Distribution) in the 
Nigerian pharmaceutical sector(Garuba et al., 2009). The authors conducted the study from 




which provides both qualitative and quantitative data on the transparency to corruption in each 
stage of the four functions of the public pharmaceutical sector. Furthermore, Kanj Goyit et al 
highlighted that the capacity of the national, state, and local government supply chains in 
Nigeria for forecasting, procuring and delivering essential drugs and other medical needs is a 
major limitation to the smooth running of the supply chain (Goyit et al., 2016).  
 
Using standardized questionnaires which were made up of both open and closed-end questions 
where adapted from the WHO assessment tool for each of the four functions. In addition to the 
questionnaire, a semi-structured interview was carried out in person with 14 participants by 
one of the authors of the study. Key policymakers such as NAFDAC officials and stakeholders 
which represent both the public and private sectors of the pharmaceutical system were 
engaged during the interview. The 14 participants were selected based on their expertise and 
level of participation in the four functions.  The data collection was mainly done to identify 
areas that were susceptible to corruption due to the various deficiencies in governance and 
institutional weakness (Garuba et al., 2009).  
 
Based on using the WHO assessment tool the scores reflected the different levels as to which 
the four functions are exposed to corruption. The results from the study showed minimal 
vulnerability to corruption in the distribution and procurement of drugs, moderate vulnerability 
to corruption in drug registration, and marginal vulnerability to corruption in the inspection of 
goods at the port and establishments (Garuba et al., 2009). On a scale of 1-10, the findings from 
this research showed that registration of drugs is the most vulnerable to corruption because it 
scored the lowest out of 10, the overall rating was 7.4 out of 10 which shows a marginal 






Figure 3: A quantitative result showing the level of corruption in each section in Nigeria's pharmaceutical system, 
according to Garba et' al 
 
In a study titled, “Creating reliable pharmaceutical distribution networks and supply chains in 
African countries: Implications for access to medicines” the author highlighted that the 
distributor is the most critical link in the legitimate pharmaceutical supply chain and also a 
point of entry for counterfeit drugs if not guarded properly (Tetteh, 2009). According to the 
Cambodian Ministry of Health, MoH indicated that counterfeit drugs within the region are 
drugs that are not registered, deliberately produced with an incorrect or wrong active 
ingredient, or with no active ingredient. In 2001 and 2004 the MoH in Cambodia and the WHO 
reported the prevalence of counterfeit drugs such as anti-malaria, antibiotics, analgesics, 
vitamins, and steroids. In 2001 the prevalence of counterfeit drugs was recorded at 10.43% and 
in 2004 it was reported to be 21.13% (Khan et al., 2011). Also, a study conducted by C.T Lon et 
al between 2002-2003 reported that 92.7% of substandard aspirin where found in private 
outlets and in 2006 another study confirmed 58% of counterfeit anti-malaria drugs where seen 
in licensed outlets and 75%  of counterfeit anti-malaria drugs where seen in non-licensed 
outlets (Lon et al., 2006).  
 
These above reports prompted the Cambodian Ministry of Health to evaluate the 
pharmaceutical supply chain, especially on the issue of counterfeit drugs. In collaboration with 
the Department of Drugs and Food (DDF) and Kanazawa University, Japan, the Ministry of 
Health Cambodia conducted an oral interview with pharmaceutical wholesalers to assess the 
level of sensitization to counterfeit issues and compliance with DDF guidelines (Khan et al., 




medicine, however, their perception of the issue varied. 8.1% of respondents indicated that 
they did not know what counterfeit drugs were. 59.7 % defined a counterfeit drug as un-
registered medicine and fraudulently manufactured drugs (Khan et al., 2011).  
 
In respect to procurement, 66.1% of wholesalers consider if the product is registered in 
Cambodia, while 61.3% consider the reputation of the manufacturer, and 64.5% consider the 
credibility and quality of the product. Upon receiving a consignment 48.4% of wholesalers 
check the dates of production and expiration, 9.7% check for the analytical certificates, 80.6% 
checked the intactness of the drug,  72.6% check the specification and amount of drug, 71% 
check for Cambodian registration, 54.8% check for the batch and lot numbers and 56.5% check 
if the packaging has been tampered with. Further findings highlighted that 14.5% of the 62 
wholesalers interviewed indicated they received drugs that arrived without packaging and had 
to be repacked before distribution and 54.8% use packing purchased from the local market 
(Khan et al., 2011). 
In conclusion, the authors of this research highlighted that a good number of wholesalers are 
properly informed on the issue of counterfeiting and how to handle such cases. The authors 
recommended that to protect the pharmaceutical supply chain from counterfeit infiltration, it is 
important distributors and wholesalers are properly trained on countermeasures against 
counterfeit drugs (Khan et al., 2011).   
 
In 2012, NDDG (National Drug Distribution Guidelines) was developed to focus on the 
distribution challenges in Nigeria. This was done after concluding that the pharmaceutical 
distribution network is “fragmented and inefficient”. The repercussions of this gap in the 
distribution system have led to a large infiltration of counterfeit drugs and adulterated products 
into the supply chain (Ojo, 2017). The major goal of the NDDG amongst other goals is to 
establish an organized drug distribution system in Nigeria, which will be a joint effort of all 
stakeholders in the health sector in the country, eliminate the preponderance of unregulated 
markets (open markets) in major cities in the country, crack down the informal drug 




Unfortunately, as good as these goals sound, the major problem now is implementation. Since 
the inception of this guideline, the implementation has been constantly stalled, as at January 
2019 the implementation of the NDDG was yet to be in motion and no news has been heard 
since then (Ojo, 2017).  
 
2.4 KNOWLEDGE OF SUPPLY CHAIN MANAGEMENT 
For the proper operation of the pharmaceutical supply chain, it requires the knowledge of good 
governance practice because of the complexity associated with the supply chain system, if 
knowledge is limited, the chances of counterfeiting will be high (Enyinda and Tolliver, 2009). 
Ideally, pharmaceutical drugs are to be manufactured in a regulated and sterilized 
environment, then delivered to authorized pharmaceutical wholesalers/distributors who 
further distribute it to pharmacies/hospitals that dispense it to the end-users. However, in 
recent times, this is no longer the situation. There are now multiple steps before the end-user 
receives the medicine. The primary distributor may sell to the secondary distributor or the re-
packager or the secondary distributor might sell to the re-packager and pharmacies before it 
arrives at the end-users. These multiple transactions of distribution can go back and forth for 
months before reaching the dispensing point, this exposes the supply chain to the penetration 
of counterfeit pharmaceutical (Enyinda and Tolliver, 2009).  
 
In a publication titled “An assessment of drug supply chain system in selected facilities in Abuja 
and Plateau State, Nigeria” the authors indicated that poor infrastructure, limited human 
resources, limited materials, poor financial support and limited availability of logistics are 
specific challenges been faced by the public supply chain in Nigeria (Goyit et al., 2016). 
Furthermore, the authors highlighted that the procurement of essential drugs for hospitals and 
primary health care facilities is managed by the state while the local government areas act 
autonomously to procure products and deliver the services to the delivery points (Goyit et al., 
2016). The authors further highlighted the attributes of a properly functioning supply chain 




and swift movement of information via the supply chain to facilitate prompt response to 
customer needs (Goyit et al., 2016).  
Using a cross-sectional descriptive survey, the authors analyzed the current status of the drug 
supply chain system in selected stores in Nigeria. The survey was aimed at evaluating the 
knowledge of respondents on drug supply chain management. The findings from the 
assessment where 90% of respondents reported knowing supply chain management, 68% 
indicated to have a defined quality assessment system in place and 50% indicated that they 
have proper training in regulations, good storage procedures and safety in store (Goyit et al., 
2016). Also, the authors highlighted that 43% of respondents reported that precautions were 
not in place to prevent unauthorized people from entering storage areas and 75% indicated 
that the store was designed with good storage conditions in mind (Goyit et al., 2016). 
 
2.5 CHALLENGES OF IMPLEMENTING PHARMACEUTICAL LAWS AND 
REGULATIONS  
According to Erhun et al in a study titled “Drug Regulation and Control in Nigeria: the Challenge 
of Counterfeit Drugs,” the authors mentioned that major concerns in health development are 
drug availability, distribution, and control, particularly in Nigeria where the shortage of drugs 
and other technologies are pervasive threats to the health system (Erhun et al., 2013). The 
authors further stated that one of the major problems facing the Nigerian health care system is 
the weak drug distribution channel which has indeed posed a fractured drug supply chain of 
drugs from the manufacturer to the consumer. This has facilitated the sales and distribution of 
counterfeit drugs which have exposed Nigeria to various health risks (Erhun et al., 2013). 
 
The purpose of the study by Erhun et al was to evaluate the adequacy of the laws to minimizing 
the threat of counterfeit drugs and access the level of progress the task force in charge has 
made progress. This study was done using a questioner and an oral interview method. The 
participant of the study was regulatory (NAFDAC, and PCN) and non-regulatory (Nigerian 
Association of Industrial pharmacist, and the pharmaceutical manufacturer's group of the 




100% of respondents in the research indicated that laws were not properly implemented, 60% 
of respondents indicated that the current penalties for drug counterfeiters were too light. The 
penalties which are N5,000.00 fine or two years imprisonment were seen as too light by 
respondents which said the current fine price should be increased and the imprisonment time 
should also be increased (Erhun et al., 2013). Also, the authors stated that some responses 
suggest that, lack of proper documentation of offenders might suggest the poor 
implementation of laws.   
Furthermore, 57% of respondents indicated that corruption is a contributory factor to the 
availability of counterfeit drugs because the effectiveness of some regulatory bodies is 
negatively affected by the corruption of some officials in the Nigerian health care system. 100% 
of the respondents stated that the establishment of the task force by NAFDAC was a good 
development but the coordination, monitoring, and control by the task force was deficient. 
42.8% of these respondents attribute this deficiency to the fact that the state task force 
receives directives from a Military officer as suppose to the Chairman of the Federal task force 
(Erhun et al., 2013).  
 
Figure 4:Data from the study “Drug Regulation and Control in Nigeria: The Challenge of Counterfeit Drugs” by 
Erhun et al 
 
In conclusion, Erhun et al indicated that the pharmaceutical laws are not adequate and indeed 




urgently needs to implement existing laws, NAFDAC needs to ensure all drugs are registered 
and all offenders are prosecuted, and the prosecution proceedings should be documented 
properly (Erhun et al., 2013). Also, the task force should be funded adequately and equipped 
with the necessary equipment for their operations, and pharmacists should be vigilant and 
report any suspicious counterfeiting activities to the public, colleagues and law enforcement 
agency (Erhun et al., 2013). 
2.6. COUNTERFEIT DRUGS AND CONSUMER SAFETY 
The manufacturing and supply of counterfeit drugs have been documented as one of the major 
causes of high morbidity and mortality and has also facilitated the lack of confidence by the 
citizens in the Nigerian drug system (Uzochukwu and Chinedu- Okeke, 2017). In 2012 the 
counterfeit version of an expensive chemotherapy drug (Avastin) was flagged by the FDA to 
have not active pharmaceutical ingredient (API), instead of a cancer drug, hospital physicians 
who were unaware where administering corn-starch as supposed to the actual medication 
(Kollmorgen, 2015). The use of Mobile Authentication Service in Nigeria allows consumers to 
verify the Genuity of the product they are buying. This service helps consumers confirm the 
source of the pharmaceutical product using a mobile phone and free text message. In an 
instance where a drug is confirmed to be fake the consumer is given hotline number to call to 
report the counterfeit product directly to the appropriate authorities. The MAS feature has 
equipped consumers with the first-hand opportunity to report counterfeit cases whereby 
cutting down the previous procedure needed in reporting counterfeit drug cases (Justine and 
Ilomuanya, 2016).  
 
According to a study titled “Counterfeit Pharmaceuticals: Are the U.S Consumers Aware of the 
Potential Risk? the author stated that educating of consumers on the risk regarding counterfeit 
pharmaceuticals can be a driving force to reduce the purchasing of counterfeits drugs by 
consumers, the author also stated that if campaigns are done at grass root levels, it will also 
help to minimize the spread of counterfeit drugs (Willis, 2018). To create awareness, the 
Director-General of NAFDAC as of 2010 Dr. Paul Orhii initiated a massive public awareness 




products. Dr. Paul Orhii further stated the need to collaborate with all stakeholders and 
respondents of the Nigerian pharmaceutical supply chain to improve the quality of products 
been distributed within the country (Ojeme, 2010). China which is known as the center for 
exporting counterfeit products, established an inter-ministerial cooperative taskforce for 
combating the threat of counterfeit pharmaceuticals, besides the task force has initiated a 
public education program to raise the awareness of the public and also guide citizens on the 
legitimate channels to acquire medical treatments (Sun, 2012). Sun Lei highlighted that this 
awareness has raised consumer awareness on drug-related legal knowledge and also enabled 
consumers with the ability to identify counterfeit pharmaceuticals (Sun, 2012). 
 
With the new advancement in technology, the sophistication of pharmaceutical counterfeiting 
has equally increased, this has compelled NAFDAC to employ technological measures in fighting 
against counterfeits in the market. This has led to the introduction of various anti-
counterfeiting technologies to detect fake drugs. These anti-counterfeiting technologies are 
TruScan device (based on Raman Spectroscopy), Radio Frequency Identification (RFID), Black 
Eye, and Mobile Authentication Service (MAS) via the use of Short Message Service (SMS) 
(Justine and Ilomuanya, 2016). Through drug authentication, consumers can avoid purchasing 
counterfeit medication, and also play a part in reporting the counterfeit drugs. The use of the 
MAS feature allows consumers to anonymously and passively provide key information to law 
enforcement agencies regarding the location of a counterfeit product anytime the 
authentication process for a drug fails. The MAS feature aims to give consumers the right to 
know the quality of the product they are buying and improve consumer health and quality of 
life (Oyetunde et al., 2019).  
 
In a research paper titled “Securing the pharmaceutical supply chain: As a study of the use of 
Mobile Authentication Service (MAS) among the Nigerian populace utilizing antimalarials,” the 
authors evaluated the effectiveness of MAS in curbing the threat counterfeit antimalaria 
medicines. The research assessed the knowledge, attitude, and level of use of MAS technology 




of 900 questioners were administered to assess the awareness of Nigerians on the availability 
of the MAS feature on anti-malaria and their knowledge of the correct use of the feature to get 
the necessary information about the authenticity of the product. Out of the 900 questioners 
the author received a total of 774 responses back. (Justine and Ilomuanya, 2016). Findings from 
the research indicated that over 70% of respondents were aware of the MAS feature. However, 
a poor response to the level of utilization was recorded; 50.1% of the respondents do not use 
the MAS feature at all, while 22.2% of the respondents indicated average utilization of the MAS 
feature and only 27.7% of the total number of respondents expressed high use of the MAS 
feature. Also, from the number of respondents that use the MAS feature, 48.8% of these 
respondents received positive feedback up send the pin, while 4.7% indicated not receiving any 
feedback response (Justine and Ilomuanya, 2016).  
 
In conclusion, the authors indicated that drugs in high demand such as antimalaria medicine are 
targets for pharmaceutical counterfeiters, though MAS does not provide the biopharmaceutical 
content of the drug, it confirms the authenticity and source of the drug, whereby guarding 
against the infiltration of counterfeits into the supply chain (Justine and Ilomuanya, 2016).   
According to Job Imharobere Eronmhonsele on his assessment of the use of MAS in Edo State, 
Nigeria, using a qualitative and exploratory approach he indicated that the awareness of the 
MAS feature in the study carried out varied, but in general, the awareness of the MAS feature 
in the rural areas was poor. Furthermore, some of the challenges he highlighted from his 
research are, respondents in the rural area complained of slow response time which was mainly 
attributed to bad network within the area, most drugs not having a label at all, consumers 
purchasing unpacked drugs and conflicting message, which means receiving a text stating a 
drug is genuine while it was fake or vice versa. These challenges have left the resident of these 
areas doubting the efficacy of the MAS feature (Eronmhonsele, 2015). The author concluded 
that the awareness of the MAS feature within the area (rural area) of the study was low as 





In conclusion, the author recommended that further research be carried in other areas of the 
state and more awareness should be done to enlighten the public on the use of the MAS 
feature. In a bid to confirm the challenges related to the wrong text message and the slow 
response, the author interviewed the NAFDAC regional head of the area and he confirmed the 
challenges but could not give a concrete response on when the challenge will be resolved. The 
author indicated the need for this to be sorted on time so the implementation of the MAS 
feature especially in rural areas does not fade out (Eronmhonsele, 2015).  
 
2.7 COMPARATIVE REVIEW: A UNITED STATE STUDY  
According to the Pharmaceutical Security Institute (PSI), a non-profit organization which 
constitutes pharmaceutical companies' security directors, between 2005 to 2010, a 66% 
increase in pilfering and diversion of pharmaceuticals was recorded. During this same period, 
the number of counterfeit activities increased by 122% (Pharmaceutical Security Institute, 
2019). Subsequently, other international bodies such as the United Nations Office of Drugs and 
Crime, WHO, Institute of Medicine (IOM) and National Association of Boards of Pharmacy, also 
reported the need to protect the global medicine supply chain because of the upsurge in the 
challenges constantly faced. Despite these reports and investigations done, the exact depth of 






Figure 5:Pharmaceutical Crimes in Different Regions of the World 
 
The increase in the prevalence of counterfeit drugs is a problem for pharmacists, 
pharmaceutical companies, and patients as well. According to Lakeisha Williams and Ellen 
Mcknight, they stated that the magnitude of the problem cannot be gauged properly because, 
the production and selling of counterfeit drugs are only known when the preparator has been 
caught, which makes the gathering of data difficult. The World Health Organization (WHO) 
estimated that 10 percent of the global pharmaceutical commerce contains counterfeit drugs 
(Williams and McKnight, 2014). The issue of drug counterfeiting has provoked great concerns 
across borders. In a study done by WHO, 48.7 percent of drug counterfeiting cases were 
reported in countries of the Western Pacific particularly China, Philippines, and Vietnam, 
followed by developing countries in Africa which accounted for 18.7 percent. In Europe, the 
industrialized areas accounted for 13.6 percent of reported counterfeiting cases, and 
approximately 1% of counterfeit medications are sold in the US, although these numbers 
increase annually (Williams and McKnight, 2014).  
 
In the United States, patient safety issues and deaths have been reported as a result of 
counterfeit drugs. As the world’s largest market for pharmaceutical sales, the United States is 




exempted from the threats of counterfeiting, blockbuster drugs such as Lipitor had to be 
recalled due to the discovery of their counterfeit versions on sale (Mackey and Liang, 2011). 
Furthermore, in 2010, the FDA had discovered the counterfeited version of generic Tamiflu, 
which was never certified by the FDA as a generic product. To make matters worse, 
independent consumers are not the only victims of these counterfeit drugs; they have also 
been discovered in hospitals and pharmacies in the U.S. A relevant discovery Mackey and Liang 
shows that the major source of these counterfeits was through “gray markets” (Mackey and 
Liang, 2011). Gray markets in the United States are secondary markets that take advantage of 
the loopholes in the distribution supply chain to slip counterfeit drugs. Additionally, these 
counterfeiters may also use stolen drugs which can be diverted to criminal parties for illegal 
sales (Mackey and Liang, 2011).  
 
To control the distribution of counterfeit medication, the FDA and pharmaceutical industry use 
two major fronts: packaging and dosage form authentication systems. In addition to these 
authentication systems, pharmacists are advised to closely and carefully examine all 
pharmaceutical products. Also, in addition to the present measures to reduce how counterfeit 
drugs enter the supply chain, a total of 18 states in the United States have adopted a regulatory 
approach by using the “normal distribution” model for the distribution of pharmaceutical 
products. This model requires wholesalers to purchase prescription drugs from an “established 
customary supply chain” i.e. purchasing drugs solely from the manufacturer or an authorized 
agent by the manufacturer as defined by law (Chambliss et al., 2012). In a case whereby the 
wholesaler does not obtain the pharmaceutical products from these sources, the wholesaler is 
expected to provide the buyer with a document known as a pedigree. A pedigree is a document 
that documents the movement of products through the normal distribution channel. The 
pedigree document requires that every person involved in the distribution of a drug, which is 
not an authorized distributor or the manufacturer, is required to present a pedigree to the next 





To secure the pharmaceutical supply chain in the United States, the White House Counterfeit 
Pharmaceutical Inter-Agency Working Group has recommended that the track and trace system 
should be adopted to monitor all pharmaceutical products and related products. In line with 
this, the USFDA (United States Food and Drug Administration), issued guidance on the use of 
standardized “numeric identifiers” to create a unique “license plate” to monitor individual drug 
packages in the supply chain (Chambliss et al., 2012). Also, to reduce the sales of counterfeit 
drugs, the Institute for Safe Medication Practices recommends the use of a “standardized 
prescription verification process” in all pharmacies. This was recommended because reports 
also showed that pharmacies that used imaging and scanning technologies as part of the 
prescription verification process made fewer medication errors (Chambliss et al., 2012).  
To ensure the credibility of distributors, (National Association Board of Pharmacy) NABP in the 
United States has an accreditation program for distributors. The criteria reviewed during the 
accreditation process are licensure verification, operating procedure, an inspection of facilities, 
screening of clearinghouse, and background checks. Facility accreditation is done every year 
while the site survey is done every 3 years (Chambliss et al., 2012). 
 
According to Boumil et al in a publication titled “ Whistleblowing in the Pharmaceutical Industry 
in the United States, England, Canada, and Australia”, Since 2000 via the implementation of the 
whistleblower policy in the pharmaceutical industry in the US, the Department of Justice has 
investigated dozens of major cases involving allegations of fraud and abuse on the part of 
pharmaceutical manufactures related to specific drugs (Boumil et al., 2010). Furthermore, the 
authors stated that the implementation of the whistleblower policy in the pharmaceutical 
sector exposed an illegal market scheme that promotes off-label (unapproved) use of an 
approved drug by a pharmaceutical company. This is against the Food, Drug, and Cosmetics Act 
which states drugs approved for specific (‘intended’) uses and thereafter physicians can 
prescribe them for any use, including those ‘off-label’. In this case, the manufacturers are not 
allowed to market or promote the drug directly or indirectly. Boumil et al concluded that the 
use of the Whistleblower policy has proved to be a significant tool in exposing false claims and 





2.8 CONCEPTUAL FRAMEWORK  
 
Figure 6: Conceptual Framework 
 
This conceptual framework is developed based on the recurring subject and themes in the 
literature review. This framework shows the sources of counterfeit drugs in the supply chain, 
the impact of these counterfeit drugs, the reason why much progress has not been made in 
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CHAPTER 3: RESEARCH METHODOLOGY 
3.1 OVERVIEW 
Section  Primary Data  Part A Part B 
1. Method Qualitative Analysis  Quantitative Analysis  
2. Philosophy  Pragmatism Pragmatism 






4. Structure 10-25 minutes of 
Interview 
Consumers: 5 
sections made up of 
20 questions  
Pharmacist: 6 
sections made up of 
21 questions  





Table 1:Research approach and Method of Data Collection. 
 
3.2 RESEARCH METHODOLOGY  
This section is important for each analysis since the validity of the research largely depends on 
the research method used and the quality of data gathered. In this section, the researcher 
applies the use of a qualitative method via zoom & phone interviews and a quantitative method 
via questionnaires to gather data. Using a mixed-method, the researcher employed these 
methods to analyze the loopholes in the pharmaceutical supply chain and methods for 





The research cohort was made up of pharmaceutical distributors, pharmacists, and consumers. 
The method of data collection for each group varied, a zoom & phone interview was used for 
pharmaceutical distributors and pharmacists while a google generated questioner was 
distributed to consumers and pharmacists as well. The purpose of the questioner was to enable 
the researcher to gather appropriate data and information to facilitate correct statistical 
analysis. The questioner administered to the consumers was aimed to evaluate the current 
level of acceptability of current technologies available for minimizing the spread of counterfeit 
drugs and further assess the factors which influence the purchasing decision of consumers. 
While the questioner administered to pharmacists aimed to evaluate basic knowledge on 
supply chain management, assess knowledge of anti-counterfeit technology, and gauge their 
response to their role in fighting counterfeit drugs. 
  
The interview aimed to gain new ideas and personal perception from both distributors and 
pharmacist while gaining knowledge on the current state of the pharmaceutical supply chain 
and also gaining new knowledge on factors which hinder the successful implementation of 
laws. These recommendations were placed under various themes which gave the researcher an 
insight into giving a sustainable conclusion. Also, the data gathered from both groups were 
compared to data from the secondary data (literature finding) to facilitate the researchers' 
conclusion on the research study.  
3.3 RESEARCH PHILOSOPHY  
Research philosophy is the belief or approach used in gathering, interpreting, and evaluating 
data. This research explores the pragmatism philosophy because this philosophy explores the 
plurality of methods. The pragmatism philosophy is based on the proposition that researchers 
should use both philosophical and methodological approach when researching a topic. The 
pragmatic philosophy is mostly associated with mixed methods or multiple method research 
approach (Kaushik and Walsh, 2019).  
This research philosophy was used for this research based on the philosophy which it 
represents. The pragmatic philosophy was implemented using both the qualitative and 




and gain insight from their knowledge of the topic. It was also used to explain the information 
gathered from participants which facilitated the researcher in making an applicable conclusion 
for the research. Also, it was used to collect basic information from pharmacists and 
understand consumer position on existing technologies. The data collected was used to help 
the researcher have a more valid conclusion. Using an inductive method development of 
themes is directed by the content of the data. As stated earlier this is an exploratory research 
that aims to explore the opinion of industry experts, hence using the inductive method, themes 
extracted will be based on data gathered using the thematic analysis.  
Using a qualitative approach, the pragmatic philosophy was adopted towards data gathered 
from the interview done with Pharmaceutical Distributors and Pharmacist. The data gained 
from these interviews were from their experience thus far in the industry, their perspective on 
the subject, and their suggestions. There was no bias in this study because this research was 
independent of the researcher and there was no personal interest or human interference with 
the study. As a requirement to obtain appropriate results using the pragmatic philosophy the 
level of validity and level of depth as obtained from these professionals were inclined to be 
subjective, with a reliable and good representation of knowledge.    
 
Using a quantitative approach, towards gathering data from the consumers and pharmacists 
using a properly structured questionnaire via google forms, this was used to analyze and 
interpret data collected objectively. This part of the research had minimal to no interaction with 
participants which prevented any form of bias in the research.  
3.4 RESEARCH STRATEGY  
To gather valid and authentic data they are seven ways in which it can be achieved, but for this 
research, the researcher focused on interviews and questioner. To analyze the loopholes which 
exist in the pharmaceutical supply chain and propose methods for improvement, the researcher 
evaluated the awareness of consumers of the present technologies, the perspective of the 
distributors and pharmacist on the current state of the pharmaceutical supply chain and their 
views as well on the poor implementation of laws within the pharmaceutical supply chain. As 




improve the infiltration of counterfeit drugs into the pharmaceutical supply chain. Also, no 
study has been identified which includes consumers, pharmacists, and distributors within the 
country, to ascertain the depth of knowledge of the current technologies available to control 
the spread of counterfeit drugs. Furthermore, as mentioned above the implementation of 
policies has been poor, hence during this research, lessons from other countries that have 
successfully managed the situation will be used as a basis to also support this study. 
 
The major participants of this research where pharmaceutical Distributors, Managers or 
Owners of Pharmacies and Consumers in general. Distributors and Pharmacists were duly 
informed of the purpose of the research and the confidentiality of their responses. The purpose 
of the research was explained properly on the first page of the questionnaire and the 
permission of participants was requested before proceeding to respond to the questions. 202 
consumers responded to the consumer questioner and 55 pharmacists responded to the 
pharmacist questioner. 6 distributors were interviewed, and 7 pharmacists were interviewed.  
 
All questionnaires were generated online and filled in the absence of the researcher. The 
consumer questioner consisted of five sections with 20 questions in total while the pharmacist 
questioner had six sections with 21 questions in total. All questions were asked according to the 
objective of the research.  
3.5 COLLECTION OF PRIMARY DATA 
The collection of data was done via two methods, primary and secondary data collection. 
Secondary Data collection was done via Literature reviews and primary data collection was 
done via the use of qualitative and quantitative methods respectively. The collection of primary 
data was done via interview and questioner. The primary research via the qualitative research 
method was done through a semi-structured interview whereby addressing the main objective 
of the research. These interviews were done with pharmacist-owners and managers who have 
held the position for a reasonable number of years.  The position and years of experience 




these positions, will have more access to the ordering and supply of the drugs, and the more 
the years the more the experience.  
All questions administered during the interview were structured in line with the objective of the 
research, each question fell under one of these groups, assessment of the knowledge of supply 
chain, knowledge of distribution laws, and knowledge of anti-counterfeit technologies.  
The author used both qualitative and quantitative analysis for the pharmacist group because 
the questionnaire alone, will not give the researcher the liberty to probe deeper or ask further 
questions, but that can be done during an interview. The combination of the two methods gave 
the researcher access to more pharmacists to gain the basic data, while the interview gave the 
researcher more information, and the opportunity to probe deeper into the response of 
participants. The interview process also gave the researcher new insights, fresh perspectives, 
and more information. 
 The interview approach was used for only distributors because access to distributors was 
limited and the need to ask more questions was necessary because there is a gap with this 
study involving distributors.  The questioner approach was used for consumers to gather 
statistical data of current responses to existing technologies and also have a knowledge of 
trends and patterns associated with response to existing technologies.  
Each section of the interviews and questioner covered all the objectives of the research, 
knowledge of current technologies, knowledge of pharmaceutical distribution laws, assessment 
of the pharmaceutical supply chain, Knowledge of anti-counterfeit technology, and NAFDAC 
Assessment and for consumers’ willingness to try new technologies.  
3.6 PROCEDURE AND SAMPLE  
To test the validity and reliability of data collected a pilot study of six participants was 
conducted of the questions. This pilot study gave the researcher direction on how to structure 
the question better. A total of 270 participants participated in this research, this comprised of 
202 consumers and 55 pharmacist responses to the questionnaire, and a total of 13 interviews, 
comprising of 7 pharmacists and 6 distributors.  
All interview participants were well-experienced stakeholders in the industry and had over 5 




introductory paragraph was written in the first section of the questioner. All participants 
volunteered willingly and were glad to be part of the study. The researcher got participants 
from LinkedIn, and Referrals from friends and family. Questionnaires were filled at the 
participant's convenience and Interviews were held at the participant's time and convenience. 
Before each interview was recorded the researcher asked the participants if they were 
comfortable with it. 
 
3.7 ACCESS AND ETHICAL ISSUES  
All participants were given a brief introduction of the topic both verbally and in a written form, 
to ensure all participants were duly informed of the research and the purpose of the research.  
All participants were asked for verbal approval before proceeding with the interview and 
participants who responded no to voluntarily participating in the survey, the form automatically 
submitted to prevent any form of involuntary response. 
All questions were structured with caution and the identity of participants was kept 
anonymous. The questions allowed participants to respond freely without any form of coercion 
to prevent any form of bias. The choice of participation was strictly the prerogative of the 
participant and participants were permitted to withdraw from the study at any time.  
 
3.8 INCLUSION AND EXCLUSION CRITERIA  
The primary participants of this study were Pharmaceutical Distributors and Pharmacists to 
understand their view of the current state of the supply chain and gain new perspectives from 
their experience. While the consumers where secondary participants to access their current 
knowledge and openness to new technologies. The inclusion criteria for pharmacists where 
owners and managers of pharmacies who are actively involved in drug order and lias more with 
distributors. Distributors were automatically excluded if they were not willing to participate in 
the study. As mentioned earlier participants who declined to respond to the questionnaire 
were excluded from the study.  
An introductory section was attached to the questionnaire and an introduction was given by 




discretion and were duly informed of their right to withdraw at any time during the cause of the 
study.  
 
3.9 CONCLUSION  
The methodology applied in this research was a pragmatic philosophy, the researcher applied a 
mixed-method approach considering the two types of participants involved in the study. The 
data collection was a combination of online distributed questionnaires and a semi-structured 
interview with industry stakeholders (distributors and pharmacists), which amounted to a total 
of 270 participants in total.  
The data collected was analyzed and compared to the results and conclusions gotten from the 
literature review. The researcher uses both qualitative and quantitative approaches to 
understand the level of awareness of the consumers on the present technologies and also gain 
new insights and learn from the experience and perception of industry experts' response and 
also get new suggestions and recommendations.  


















CHAPTER 4: FINDINGS AND ANALYSIS  
4.1 OVERVIEW 
This chapter evaluates the response on the state of the pharmaceutical distribution system in 
Nigeria, access the challenges faced with effectively implementing supply chain laws and 
reforms, analyzes the participant's knowledge on supply chain management, and evaluates the 
consumer's awareness of current technologies. As mentioned earlier no sufficient literature has 
been identified that included the distributors and consumers in the analysis in the country. 
Hence to analyze the interview data the researcher will be engaging the use of Thematic 
Analysis; this method is referred to as the method in which patterns and topics are defined 
analyzed and interpreted. The researcher used this method of analysis because it is a flexible 
method that allows the researcher to find themes where there are no clear ideas of what 
patterns or themes been sort for in exploratory research. This works well for the researcher 
because she is using an exploratory method, whereby exploring views of industry experts. The 
data from the interviews directed how the themes where developed.  
The survey for the pharmacies was conducted to get basic information concerning the topic and 
access their knowledge of the topic. The survey for the consumers was done to evaluate their 
knowledge of the current anti-counterfeit technologies present and their willingness to 
embrace new technologies. The survey data were analyzed and interpreted using Microsoft 
Excel. 
Response Rate: A total of 20 people were scheduled to be interviewed, 10 distributors, and 10 
pharmacists. A total of 13 participants responded to the interview, 7 pharmacists and 6 
distributors with two responding via text, recording a response rate of 65%  
The survey was distributed to a total of 370 participants. 70 pharmacists and 300 consumers. A 
total of 55 pharmacists responded to the survey and a total of 202 consumers responded to the 
survey giving a total of 257 responses. Hence, recording a response rate of 69.45%.  
4.2 FINDINGS (QUALITATIVE DATA) 
For better understanding, the themes found during the interview will be listed for a better 
understanding of this section. The response of participants will be represented in quotes which 




A total of 10 pharmacists were scheduled to be interviewed, but only 7 responded to the 
interview. A total of 10 distributors were scheduled to be interviewed, 2 preferring to respond 
via email, but no response was recorded and 1 not responding to either calls or text. A total of 6 
participants responded to the interview, with 2 responding via text.  
All pharmacists who were interviewed fell into this category, they have been practicing 
between 3 to 20 years and have either owned or managed a pharmacy between 1 to 15 years. 
Out of the 7 pharmacists interviewed 4 were managers and 3 were owners.  
All distributors who participated in the interview process have been in the business for more 
than 5 years. 4 participants responded via phone interview while two responded via text.   
4.3 DISCUSSION OF THEMES    
From the response during the interview, the two groups of industry experts were interviewed 
with different questions and some similar questions, some themes from both groups kept 
occurring. Recurring themes during the interview where the open market, unskilled people, 
greed & corruption, awareness, poor supply chain management system, and improvement of 
current anti-counterfeit technologies. 
4.3.1 Open Market 
This theme constantly occurred during the interview, though they were no questions directly 
asked about open markets in both interviews carried out with each group of participants the 
conversation on the open markets came up.  
According to most of the participants for both groups, when asked “what aids the supply of 
counterfeit drugs”, a significant number of them responded with the presence of “open 
markets”. According to 4 of the participants they likened the people selling in the open markets 
to “traders”. Repeated amongst 7 participants they highlighted that these people are out to 
make profit and do not care about the consumer's health or safety. According to a participant 
he mentioned that; “In Nigeria, they are people who are not pharmacist who own distribution 
outlets, they are traders, they have no integrity and are more concerned with buying and selling 
and will do anything to make money”  
Also, two participants one from the distributor group and one from the pharmacist's group 




highlighted that “during the out of stock period some counterfeiters quickly take advantage of 
the period, send a sample of the scarce product to countries like China and quickly dup the 
packing, the batch number, and other features similar to the product and bring it back into 
Nigeria and sell”. The second stated that; “when there is stock out some dubious people even 
wholesalers go to China and duplicate the packs of these drugs, make something else, write on 
the body and supply. And because it is in high demand, people don’t look carefully, they just 
buy”. This implies that the presence of the open market indeed poses a challenge to the 
pharmaceutical supply chain and also aids the infiltration of counterfeit drugs.  
4.3.2 Unskilled People  
Unskilled people, untrained and non-professionals, these were themes that also re-occurred 
during the interview process. The presence of unskilled people was highlighted by participants 
to be part of the factors which facilitate the loopholes in the supply chain. This is because the 
regulatory body in charge of approving does so without a thorough check of applicants. These 
unskilled people according to a participant “they are part of the driving force behind the spread 
of counterfeit drugs”. Some participants also linked these unskilled people to the factors which 
aid the spread of counterfeit drugs. According to a participant He stated that “Non-
professionals and unskilled people are involved in the business of distributing drugs, but are 
more concerned with the money than the quality of the product”. This implies that the presence 
of unskilled workers facilitates the distribution of counterfeit drugs, hence as recommended by 
one of the participants it is important for the regulatory body to be strict with who they 
approve to practice.  
4.3.3 Greed & Corruption  
One of the research questions for this study is “why laws are poorly implemented?” 80 percent 
of participants responded by saying the presence of corruption and greed has affected the 
effective implementation of laws and regulations. A participant highlighted that “laws are 
poorly implemented because everything has been politicized” another participant stated that 
“Laws have been poorly implemented because of greed and corruption in the system”. For laws 
to be properly implemented members of regulatory bodies need to have integrity, that way 




4.3.4 Awareness  
All participants agreed that as pharmacists they play a vital role in reducing the spread of 
counterfeit drugs. A significant number of the participants stated they need to educate and 
enlighten consumers on the dangers of counterfeit drugs and also advise them on the need to 
purchase drugs from the right pharmacies. Furthermore, some participants also highlighted the 
need for NAFDAC to enlighten consumers on the MAS technology and the need to be vigilant 
on where they purchase drugs and also be sensitive to the kind of products they purchase. A 
participant highlighted that “More awareness on the current anti-counterfeit technologies 
should be made and people should be enlightened on how to identify counterfeit drugs” and 
another participant mentioned that  “Adequate counseling should be given to consumers on 
why they should be vigilant on where they purchase drugs from.” This implies that consumer 
awareness will help reduce the spread of counterfeit drugs.  
4.3.5 Poor Supply Chain Management System 
From the Literature review, proper supply chain management is one of the ways the infiltration 
of counterfeit drugs into the pharmaceutical supply chain can be prevented. A significant 
number of participants know about supply chain management, but according to one participant 
the “awareness of supply chain management is still coming up in Nigeria”. According to another 
participant “supply chain management has the potential to reduce the infiltration of counterfeit 
drugs into the pharmaceutical supply chain if it is properly monitored, as of now it is not 
properly monitored and I do not think Nigeria is ready to embrace it yet”. Furthermore, another 
participant highlighted the need to implement supply chain management, he stated: “ it will 
help reduce the spread of counterfeit drugs because the agency in charge of counterfeit drugs in 
Nigeria has lots of challenges, especially logistics problem which aids the infiltration of 
counterfeit drugs into the supply chain”.  Though 6 out of the 7 pharmacists interviewed agreed 
that supply chain management can reduce the spread of counterfeit drugs, one participant 
stated that “From my own experience I would say No, it can't. Within the Nigerian market, I 
don't think supply chain management can quell the bane of counterfeit drugs. The reason is that 
in the Nigerian market, there are players whose entire business is built on the production and 




make more money. We have a corrupt system in place here which thrives on such practices, and 
the lack of strong regulation and implementation of laws are already grounds that allow for 
these fraudsters to thrive and prosper. These fraudsters know how to work around NDLEA, SON, 
and NAFDAC”.  This answer indicates that if laws are not properly implemented, proper supply 
chain management will not be sufficient enough. It can be deduced that proper supply chain 
management will be good, but for the Nigerian pharmaceutical supply chain, it cannot work 
alone.  
4.3.6 Improvement of Current Anti-counterfeit Technologies.  
A significant number of participants know about anti-counterfeit technologies. The technology 
which occurred frequently was the Mobile Authentication Service (MAS) technology. The 
majority of participants agreed that it has helped a bit in reducing the spread of counterfeit 
drugs but it needs to be improved. One participant highlighted that “it has not been effective 
enough because most drugs don’t carry the MAS feature.” Another participant stated that “MAS 
technology has not sufficiently helped because the response time is slow, and sometimes it 
takes up to 3 days to receive a response and sometimes consumers receive false replies, genuine 
drugs are tagged as fake and vice versa.” While another participant mentioned that “MAS 
technology has helped cut down the spread of counterfeit drugs but not enough. More 
enlightenment needs to be done because many people are not aware of it”. This implies that the 
MAS feature has the potential to minimize the spread of counterfeit drugs, but it needs to be 
improved for it to be effective.  
In conclusion, from the data gathered above, it can be deduced that the presence of unskilled 
workers, and open market, are the drivers that aid the infiltration of counterfeit drugs. It can 
further be extracted that, the poor implementation of laws is a result of greed and corruption 
on the part of the regulatory bodies. This factor was also mentioned in a study by Erhun et al as 
a contributory factor, where the "effectiveness of some regulatory bodies is negatively affected 
by the corruption of some officials in the Nigerian health care system" (Erhun et al., 2013). 
Some of the challenges the open market pose are during the out of stock period, a lot of 
counterfeit drugs are produced and supplied to unsuspecting pharmacists and consumers. 




reforms recommended is the need to facilitate awareness amongst consumers and for 
distributors to buy from the approved pharmaceutical supply chain. Finally as mentioned by 
two participants, border controls need to be enforced strictly to monitor the drugs coming into 
the country.  
4.4 FINDINGS (QUANTITATIVE DATA)  
4.4.1 CONSUMER ANALYSIS DATA REPRESENTATION  
DEMOGRAPHICS 
Frequency Percentage 
1. I agree to voluntarily participate in this research study and give 
consent to my response been used for research purposes.       
Yes 202 100% 
No 1 0% 
2.Gender      
Female 107 53% 
Male 95 47% 
3. Age      
18-30 130 64% 
31-40 35 17% 
41-50 19 9% 
50 and older 18 9% 
4. Highest Level of Education     
No formal education 1 0% 
Postgraduate 129 64% 
Secondary School 5 2% 
Undergraduate 67 33% 
5. Occupation      
Employed 82 41% 
Retired 4 2% 
Self-employed 43 21% 
Student 64 32% 
Unemployed 9 4% 
6. Area of Residence     
Rural 22 11% 
Small town 1 0% 
Urban 179 89% 
Table 2: Demographics 
The purpose of this section is to study the characteristics of the population based on their age, gender, 
occupation, area of residence, and education. The ratio of females to males was 53% to 47%. The ratio 
of participants residing in rural areas to those in the urban was 11% to 89%. This section of the interview 




KNOWLEDGE OF EXISTING ANTI-COUNTERFEIT TECHNOLOGY  
Frequency  Percentage  
7. How often do you scratch the code to check the authenticity of the 
drugs?     
Always 16 8% 
Never 65 32% 
Often 15 7% 
Rarely 51 25% 
Sometimes 55 27% 
8. Are you aware of the Mobile Authentication Service to verify the 
authenticity of the drugs you purchase?     
No 41 20% 
Yes 161 80% 
9. How did you get to know about the Mobile Authentication Service?     
10. Is the Mobile Authentication Service, User Friendly?     
No 9 4% 
Not Applicable 75 37% 
Yes 118 58% 
11. How will you rate the response time of the Mobile Authentication 
Service?     
1 20 12% 
2 7 4% 
3 62 38% 
4 42 26% 
5 32 20% 
Table 3: KNOWLEDGE OF EXISTING ANTI-COUNTERFEIT TECHNOLOGY 
 
This section was required for the researcher to propose new methods, to propose new methods she will 
need to know how well the current methods are been used by consumers. This will help her direct her 
recommendations for either new technologies or more improvements. From the above response 80% of 
participants are aware of the MAS technology, but those who used it always or often where 8% and 7%. 
58% of respondents admitted that the feature is friendly but 38% rated the response time 3 over 5 
which can be interpreted as fair.  
This implies that the majority of participants are aware of the MAS feature but as seen in the table 









ASSESSMENT ON RESPONSE TO COUNTERFEIT DRUGS  
Frequency  Percentage  
12. Have you ever had an encounter with counterfeit drugs or do you 
know anyone who has?     
No 114 56% 
Yes 88 44% 
13. In your opinion, do you think consumers can help reduce the 
spread of counterfeit drugs?     
No 21 10% 
Yes 181 90% 
14. If you scratched the code and realized the product is counterfeited, 
will you?     
15. [How likely will the price of a drug affect your buying decision?]     
Likely 64 32% 
Most Likely 57 28% 
Most Unlikely 12 6% 
Neutral 44 22% 
Unlikely 25 12% 
Table 4:Assessment on Response to Counterfeit Drugs 
 
This section weighs in on the current performance of the current technology available to consumers to 
verify the authenticity of the product purchased. This gives the researchers an insight into factors that 
influence the consumer's decision and allows the reader to view how consumers purchase drugs. 44% of 
respondents have had an encounter with counterfeit drugs and 28% and 32% of respondents agreed 
that the cost of a drug will most likely and likely affect their buying decision.  
This data implies that a good number of participants have not encountered counterfeit drugs and  90% 













NAFDAC ASSESSMENT  
Frequency  Percentage  
16. How will you rate the government’s effort in fighting against the 
spread of counterfeit drugs?     
1 41 20% 
2 52 26% 
3 83 41% 
4 19 9% 
5 7 3% 
17a. [In your opinion, will you agree that the government is effective at 
communicating the risk of counterfeit drugs in Nigeria]     
Agree 66 33% 
Disagree 48 24% 
Neutral 58 29% 
Strongly Agree 13 6% 
Strongly Disagree 17 8% 
17b. [In your opinion, will you agree that NAFDAC has done a good job in 
publicizing the use of the MAS feature?]     
Agree 65 32% 
Disagree 32 16% 
Neutral 76 38% 
Strongly Agree 17 8% 
Strongly Disagree 12 6% 
17c. [In your opinion, do you think the MAS feature should be applied to 
all drugs. ]     
Agree 74 37% 
Disagree 3 1% 
Neutral 35 17% 
Strongly Agree 87 43% 
Strongly Disagree 3 1% 
18. If NAFDAC published a list of Licensed pharmacies within your area will 
you adhere strictly to it?     
Yes 194 96% 
No 8 4% 
19. Would you be open to using new technologies to help minimize the 
spread of counterfeit drugs?     
Yes 198 98% 
No 4 2% 
20. Do you think the whistleblower policy will be useful in reducing the 
distribution of counterfeit drugs in Nigeria?     
Yes 183 91% 
No 19 9% 




This section was used to evaluate the efforts of the regulatory body from the consumer's perspective. 
This section was needed to help the researcher evaluate the performance of the regulatory bodies and 
access consumers' willingness to help reduce the spread of counterfeit drugs.  
This data implies that NAFDAC has made sufficient effort so far, but needs to work on consumer 
awareness, application of anti-counterfeit features to more drugs and consider the use of some new 
methods to reduce the spread of counterfeit drugs. 
 
4.4.2 PHARMACISTS DATA REPRESENTATION  
DEMOGRAPHICS  
Frequency Percentage 
1. I have read and understood the information and I voluntarily agree to participate 
in this research study.      
No 0 0% 
Yes 55 100% 
2. Gender     
Female 26 47% 
Male 29 53% 
3. Age      
18-30 12 22% 
31-40 21 38% 
41-50 17 31% 
50 and older 5 9% 
4. Highest Level of Education     
Bachelor's Degree 33 60% 
Masters Degree 20 36% 
PhD 2 4% 
5. Which of these roles do you hold?     
Pharmacy Manager 38 69% 
Pharmacy Owner 17 31% 
6a. How long have you been practicing in this field?     
1-5 years 19 35% 
6-10 years 18 33% 
Less than 1 year 3 5% 
Over 10 years 15 27% 
6b. How long have you managed or owned your pharmacy?     
1-5 years 23 42% 
6-10 years 13 24% 
Less than 1 year 10 18% 







 This section was needed to help the researcher access the background of the health professionals filling 
this questionnaire. The two roles were pharmacy owner or pharmacy manager because these are the 
two roles directly involved with the order and receiving of drugs.  This questionnaire had more 
responses from the pharmacy mangers which was 69% while the pharmacy owners were 31%.   
Table 7:Assessment of Supply Chain Management 
 
This section was to evaluate if participants have a knowledge of supply chain management. 98% of 
respondents showed they know about supply chain management, where 85% showed they learned in 
school.  
From the data gathered above, it can be extracted that the majority of pharmacists know about 





ASSESSMENT OS SUPPLY CHAIN MANAGEMENT  
Frequency  Percentage  
7. Do you know what pharmaceutical supply chain management is?     
No 1 2% 
Yes 54 98% 
8. How did you learn about it?     
Learned in school (Relevant textbooks and Journals) 47 85% 
Pharmaceutical Newsletter 2 4% 
Self-Taught (Internet/ Social media) 3 5% 
Took a PGD course in logistics and supply chain management. Also did various certification 
courses. 1 2% 
Word of Mouth (Interaction with colleagues and experts) 2 4% 
9. Aside from checking the supply of drugs to confirm if the products delivered corresponds 
with your order, do you check to confirm if they are genuine?    0% 
No 2 4% 





Table 8:Evaluation of Staff Assessment 
This section gives the researcher insight into how well staffs are trained to ensure they are aware of the 
necessary measures in place to prevent sales of counterfeit drugs and can also identify the counterfeit 
product.  
 
COUNTERFEIT PRODUCTS   
Frequency  Percentage  
13. Have you ever been supplied counterfeit drugs?     
No 42 76% 
Yes 13 24% 
14. If yes, which of these did you do      
Contact distributor & report to authorities  7 15% 
Contact the distributor 6 13% 
Discard products and inform colleagues  1 2% 
Report to authorities  33 70% 
15. Who is responsible for reporting counterfeit drugs? (Choose all that apply)     
Consumers 6 11% 
Healthcare Professionals (Doctors/Nurses/Pharmacist)  44 80% 
Pharmaceutical Distributors 3 5% 
Pharmaceutical Manufacturers 2 4% 
 
Table 9:Counterfeit Products 
This section is to access how much experience professionals have with counterfeit products and who is 
responsible for reporting any case of counterfeiting.  
This data implies that the responsibility of reporting counterfeit drugs is mostly the responsibility of 
Health Care Professionals and most pharmacists are ready to report to the appropriate in an event they 
are supplied counterfeit products.  
EVALUATION OF STAFF ASSESSMENT  
Frequency  Percentage  
10. Which do you consider more when hiring?     
Experience 48 87% 
Qualification 7 13% 
11. Do all staff receive training before starting?    
No 2 4% 
Yes 53 96% 




Table 10:Knowledge of Anti-Counterfeit Technology 
 
 This section is to evaluate how well the respondents knew about anti-counterfeit technology and how 
visible it is in working in Nigeria. 
This data implies that pharmacists are conversant with anti-counterfeit technologies, but the majority 
are more familiar with the MAS feature. According to Justine and Ilomuanya, they mentioned the 
introduction of new anti-counterfeit technology by NAFDAC such as Raman Spectroscopy, Black 
Eye, and RFID, but from the above data, only 4% are aware of the RFID technology and neither 
Black Eye nor Raman Spectroscopy where mentioned in the space for others. This indicates that 
NAFDAC needs to carry out more awareness on the new technologies, to minimize the spread 










KNOWLEDGE OF ANTI-COUNTERFEIT TECHNOLOGY  
Frequency  Percentage  
16. Are you familiar with anti-counterfeit technologies?   0% 
No 2 4% 
Yes 53 96% 
17. If yes, kindly choose all anti-counterfeit technologies you are familiar with?      
Colorimetry  1 2% 
Color Shifting Codes  1 2% 
Embed-Codes  2 4% 
Hologram  8 15% 
Mobile Authentication Service (MAS) 39 74% 
Radio Frequency Identification (RFID) Tags  2 4% 
18. Do you think any of these technologies will be useful and viable in fighting the threat of 
counterfeit drugs in Nigeria?     
No 0 0% 




KNOWLEDGE OF PHARMACEUTICAL DISTRIBUTION LAWS  
Frequency  Percentage  
19. Are you familiar with Pharmaceutical Distribution laws in Nigeria      
No 4 7% 
Yes 51 93% 
20. How did you learn about it?     
Learned in school (Relevant textbooks and Journals) 39 75% 
Not Applicable 1 2% 
Pharmaceutical Newsletter 5 10% 
Self-Taught (Internet/ Social media) 3 6% 
Word of Mouth (Interaction with colleagues and experts) 4 8% 
21. Will you consider upgrading your knowledge of present laws?     
No 0 0% 
Yes 55 100% 
 
Table 11:Knowledge of Pharmaceutical Distribution Laws 
 
This section is to access how well pharmacists are aware of current pharmaceutical distribution laws. 
This section will enable the researcher to know if the professionals need to upgrade their knowledge for 
policies to be effective. 93% of respondents admitted to being familiar with distribution laws and 75% of 
respondents admitted to being taught in school.  
This implies that most participants are aware of pharmaceutical distribution laws in Nigeria and are 
ready to upgrade their knowledge on it. Hence what needs to be done is for the regulatory bodies to 












4.5 GRAPHICAL REPRESENTATION OF DATA  
4.5.1 Graphical Representation of Consumer Response  
 
                             
Figure 7: Awareness of MAS  
This chart represents how well consumers are aware of MAS technology, out of the total number of 
respondents 80% are aware of the technology.  
 









Figure 8: Use of MAS  
This chart represents how well respondents use the MAS feature, showing the highest to the lowest 






















Figure 9: Can Consumers reduce the spread of counterfeit drugs? 















Figure 10: New Technology 
 
This chart further shows the respondents' willingness to try new technologies to stop the spread of 














Figure 11: Whistle Blower Policy 
 
Research from other countries shows that the whistleblower policy has helped reduce the spread of 
counterfeit drugs. To reduce the spread of counterfeit drugs the researcher intends to evaluate how 
well consumers will accept this method using this chart.  















This chart evaluates how frequent pharmacist experience the supply of counterfeit. 24% agreed 












Figure 13: Response to counterfeit drugs supply 
This chart evaluates how pharmacists report the supply of counterfeit drugs. 70% responded to 

















This chart evaluates pharmacists' responses to who is responsible for reporting counterfeit 
drugs. Where HCP is Health care professionals, PD is pharmaceutical distributors and PM is 













Figure 15: Anti-counterfeit technology 
This chart evaluates the different anti-counterfeit technologies pharmacist are familiar with. 
74% of pharmacists are familiar with the Mobile Authentication Service. The other technologies 
stated here are Hologram (HG), Embed-Codes (EC), Radio Frequency Identification (RFID) Tags, 

























Figure 16:Usefulness of anti-counterfeit technology in reducing counterfeit drugs  
All pharmacists agreed with these technologies been viable to fighting the threat of counterfeit 


















CHAPTER 5: CONCLUSION  
5.1 OVERVIEW  
This chapter highlights answers to the research questions based on data gathered via the 
primary data and further compares the results gathered via secondary data and primary data. 
Recommendations for practice and further studies are outlined and limitations faced during the 
research are stated.  
5.2 ANSWERS TO THE RESEARCH QUESTIONS  
1. What are the factors that challenge the effective implementation of Distribution Laws 
and Regulations in Nigeria, who is responsible for ensuring these laws are 
implemented? 
From the response gathered from the interview with pharmacists and distributors, it can 
be extracted that the factors affecting the proper implementation of distribution laws 
are corruption & greed, and insufficient efforts on the part of the regulatory bodies to 
implement these laws. From the survey, it is can be seen that industry experts are 
conversant with these laws, but the problem is the implementation which is majorly the 
responsibility of the regulatory bodies who act as custodians of these laws.  
The responsibility of ensuring laws are implemented lies in the hands of three people 
the government who sign the bills into power and entrust it in the hands of the 
regulatory bodies to ensure the laws are properly implemented and the industry 
experts who are supposed to follow the laws properly.  As mentioned in one of the 
interviews the government needs to look for a way to motivate and support the 
regulatory bodies better. Also, the regulatory bodies in charge need to ensure that 
people who break these laws face the full consequence of the law. Industry experts 
should also be ready to report any suspicious activities they notice to the right 
authorities.  
 
2. What reforms from other countries can be recommended to improve the 
pharmaceutical supply chain system in Nigeria and can consumer behavior help to 





From the data gathered from the consumer analysis survey, the majority of the 
respondents agreed that consumer behavior can help reduce the spread of counterfeit 
drugs. This question was mentioned as a result of the part consumers play in reporting 
illegal activities through the whistleblower policy in the United States. To evaluate if the 
whistleblower policy was viable in the Nigerian pharmaceutical industry, 91% of 
respondents agreed that yes, it will help minimize the spread of counterfeit drugs.  
From interviews with distributors, some of the procedure to become a distributor is 
similar to what is being practiced in the US. For example, the purchase of drugs from the 
established customary supply chain. In Nigeria, they are two major national distributors 
(WWCV & Assene-Laborex) that supply to other distributors. These are the major 
intermediaries between the manufacturing companies and the distributors. The 
difference between the two countries is that in the US, distributors are bound by law to 
purchase from approved distributors also known as the customary distribution chain, 
while Nigeria has no such law, which allows unregulated buyers to access and affect the 
drug supply chain. Furthermore, in the US if a distributor does not buy from the 
customary supply chain, they are expected to provide a pedigree to the retailer which 
shows the movement of drugs through the normal supply chain.  The pedigree 
document requires that every person involved in the distribution of a drug, which is not 
an authorized distributor or the manufacturer, is required to present a pedigree to the 
next person on the supply chain, till it reaches the final consumer. This is a reform that 
can be implemented in the Nigerian pharmaceutical supply chain to reduce the spread 
of counterfeit drugs.  
From the survey response majority of participants are open to trying new technologies. 
The implementation of pedigree will allow consumers to verify the origin of drug 
products they purchase and also validate the authenticity. As recommended by industry 





3. What are the loopholes in the pharmaceutical distribution system in Nigeria that 
facilitate the infiltration of counterfeit drugs and what are the challenges faced with 
closing the open markets in Nigeria? 
According to responses from the interview with industry experts, they highlighted that 
as long as you buy from the right source, the chances of been supplied counterfeit drugs 
are very minimal. Though two participants from the interview mentioned they purchase 
from open markets sometimes, they quickly added they ensure they check what was 
purchased, but this does not change the risk associated with purchasing from the open 
market. This might also imply that occasionally distributors might purchase products 
from open markets whereby increasing the risk of purchasing counterfeit drugs.  
The data gathered from the interview highlighted that the loopholes in the 
pharmaceutical distribution channel which facilitate the infiltration of counterfeit drugs 
are the open market which is a result of greed and poverty, other factors which 
facilitate these loopholes are corruption,  poor implementation of laws, and the 
presence of unskilled individuals in the channel.  
The challenges faced with closing down the open market is the regulatory body in 
charge is not strict with who they register to practice, this is where the problem of 
unskilled individuals comes in as well. Furthermore, the problem of the weak regulatory 
structure has allowed these open markets to keep running.  
As obtained from secondary data, Chukwu et al stated that the distribution system in 
Nigeria is highly affected by poor management, insufficient and an inadequate number 
of qualified workers. An inadequate number of qualified workers was also mentioned by 
some participants during the interview as one of the challenges currently faced by the 
pharmaceutical distribution system in Nigeria. The insufficient number of qualified 
workers is one loophole that has facilitated the infiltration of counterfeit drugs and has 
also made it difficult for the government to shut down these open markets. As 
recommended by one of the participants, the regulatory body in charge of registering 
pharmacists and giving license should be more thorough and strict to who they approve 





5.3 COMPARING RESULTS FROM PRIMARY DATA AND SECONDARY DATA  
According to a study carried out by Mark Willis he recommended educating consumers on the 
risk of counterfeit drugs can help minimize the spread of counterfeit drugs (Willis, 2018).  
Furthermore, according to previous research, China also launched a public awareness program 
to create awareness on the legitimate channels to acquire medical treatment. This awareness 
enabled consumers to identify counterfeit products. This recommendation can also be seen in 
the response from industry experts who were interviewed were a significant number of them 
recommended that consumers should be educated and counseled on the risk of counterfeit 
drugs and the need to purchase drugs from the right pharmacies  
 
From the results gathered from the interview, it aligns with data gathered from Erhun et al 
study on Drug regulation and Control in Nigeria: the challenge of counterfeit drugs. Participants 
in the interview mentioned that weak distribution law, corruption, poor implementation of 
laws and shortage of drugs are all ways in which counterfeit drugs penetrate the system. Where 
57% of Erhun et al respondents stated corruption was part of why laws were not implemented, 
80% of interview participants for this study mentioned corruption is part of the problem. Also, 
where 60% of respondents from previous research agreed to counterfeiters penalities been 
reviewed 100% of interview participants of this study agreed for counterfeiters penalties to be 
reviewed.  
Justine and Ilomuanya mentioned the introduction of new anti-counterfeit technologies by 
NAFDAC such as Raman Spectroscopy, Black Eye, MAS, and RFID (Justine and Ilomuanya, 2016). 
According to the primary data majority of respondents are familiar with the MAS feature, for 
the consumers more awareness needs to be done. Though 80% agree to know it, only 8% 
percent of the respondents always use it to confirm the authenticity of drugs purchased. Data 
also gathered via pharmacist survey showed that 74% are aware of the MAS feature but only 
4% are aware of the RFID technology and no participant mentioned any of the anti-counterfeit 





According to Chukwu et al, they mentioned the factors affecting the supply chain are poor 
management and an inadequate number of qualified workers (Chukwu et al., 2017). These 
factors were also identified by participants during the interview sessions.  
The loopholes facilitating the infiltration of counterfeit drugs are the number of unqualified 
workers are more than the qualified workers, the presence of the open markets, and poor 
implementation of laws. To control the supply of counterfeit drugs more consumer awareness 
needs to be done and industry experts need to familiarize themselves with more anti-
counterfeit technologies.   
 
5.4 CONTRIBUTION & LIMITATIONS OF THE RESEARCH  
Previous studies showed gaps in studies involving pharmaceutical distributors, most studies 
where done mostly with consumers. Furthermore, previous studies only analyzed the use of 
MAS technology by consumers, but none evaluated the consumer's openness to new 
technologies and willingness to be part of a policy that reports suspicious activities. The 
pharmacist population evaluated in previous studies were not evaluated on the techniques 
they use to check products and were not accessed on their knowledge of anti-counterfeit 
technology, supply chain management, and distribution laws.  
 Based on the data obtained from this research from the 257-survey response and 13 interview 
response. The findings from this research will contribute to consumer awareness on current 
anti-counterfeit technologies available for their safety and make them conscious of where they 
purchase drugs from based on the section of the survey which analyzed consumer purchasing 
decision. Furthermore, based on the interview response and survey response, pharmacists and 
distributors will become more aware of checking products supplied and will also upgrade their 
knowledge of current anti-counterfeit technologies. 
This research will also prompt stakeholders in the Nigerian pharmaceutical supply chain to 
improve the pharmaceutical supply chain management system to minimize the logistics 





The limitations faced during this interview where slow response from participants, access to 
pharmacists who had 5 years’ experience, and more was not 100%, hence the researcher had to 
engage pharmacists with less than 5 years of experience. Access to strictly pharmacist-owners 
was not easy hence out of the 7 participants interviewed 3 were pharmacist-owners and 4 were 
pharmacist managers. Also, from the survey, a total of 55 pharmacists responded were 38 
responses where from pharmacy managers and 17 responses were from pharmacy owners.  
During the period of the interview, the network was poor hence the ability to hold video calls as 
proposed earlier was not possible. Due to this, the researcher was unable to evaluate their 
response via body language, she was only able to use the tone of their voice to validate their 
interest in the study. Unfortunately, due to time, the researcher could not interview more 
people, a total of 7 people from the two sample groups did not respond to the interview.  
5.5 RECOMMENDATIONS FOR PRACTICE  
Consumers need to be educated on the need to use the current anti-counterfeit measures 
available to help reduce the spread of counterfeit drugs and for their safety. At the moment 
only a few drug products carry the MAS feature, manufacturing companies and the regulatory 
body in charge should try and enforce the presence of the MAS feature on all drugs in Nigeria. 
Though some drugs are more counterfeited than others, all drugs are still counterfeited in the 
end. The MAS feature proved to be user- friendly but it is important that the issue of wrong 
confirmation and delayed response needs to be resolved and consumers should be encouraged 
to use the feature more. Aside from the MAS feature more visual anti-counterfeit features 
should be introduced such as Holograms for the verification of drugs because this is more 
straight forward and easy to use because sometimes a consumer's phone might not be 
accessible and those in the rural areas will benefit from the visual features as well.  
 
For industry experts, they should be educated on more anti-counterfeit technologies and they 
should also adopt the culture of checking products received despite the trust they have for the 
source, because as mentioned by some participants sometimes products are swapped and 
diverted. The introduction of pedigree or e-pedigree as used in the US in the Nigerian 




make everyone involved in the supply chain take responsibility. Also, the use of blockchain will 
be a viable technology in tracking the end to end distribution of drugs. The regulatory bodies 
should be strict in implementing laws on registering qualified people. They should also position 
competent officials at the borders to monitor the kind of drugs imported into the country.  
5.6 RECOMMENDATION FOR FURTHER STUDIES  
Further studies can be done on a larger group of participants to gain more depth and a wider 
perspective for analysis. Due to time constraints, the researcher could not interview more 
people for the interview. Also, further research can be done on the available anti-counterfeit 
technologies introduced by NAFDAC and the awareness of stakeholders. This research only 
scratched the surface of this area of the study, but it showed they are gapes in the knowledge 
of recent anti-counterfeit technologies by industry experts. Further research can look into this 
topic and propose methods to how industry experts can upgrade their knowledge. Also, further 
research can be done on the Nigerian pharmaceutical sector (registration, procurement, 
inspection, and distribution), the research can pick one sector and analyze it and propose areas 
of improvement or look at the four levels, analyze it, and propose areas of improvement. More 
research needs to be done in rural areas in Nigeria to ascertain the challenges faced with 
transporting genuine drugs to the area and how It can be improved.   
Future research can also look at the impact of poor border activities on the pharmaceutical 
supply chain in Nigeria.  
 
5.7 FINAL CONCLUSION/REFLECTION  
The research process was rigorous but was exciting, educative, and insightful. Findings from the 
research developed the researcher’s knowledge on the subject and also gave her a better 
understanding of the challenges faced by the pharmaceutical supply chain. This study also gave 
answers to questions the researcher had based secondary data and educated her better on the 
roles of stakeholders in the pharmaceutical supply chain.  
 
The loopholes in the pharmaceutical supply chain are the presence of the open market as 




these open markets which are as a result of greed and poverty are the catalyst that facilitates 
the distribution of counterfeit drugs. Corruption, poor implementation of laws, and the 
presence of unskilled individuals in the channel are factors that also facilitate the loophole in 
the pharmaceutical supply chain.  As extracted from primary data the regulatory bodies need to 
be more strict on who they approve to operate a pharmacy, this will reduce the operation of 
the open markets and also the spread of counterfeit drugs.  
 
 From primary data and literature review findings one of the methods that can improve the 
control of counterfeit drugs is consumer awareness. The need for consumers to be aware of the 
drugs they purchase and where they purchase it from is important. Also, introducing more 
visual anti-counterfeit features will help and consumers should be encouraged to use the 
current MAS feature on products.  
 
Pharmacists and distributors are advised to procure drugs from verified sources because the 
chance of buying counterfeit drugs is minimized. The government and the regulatory bodies 
should invest in more security features for the pharmaceutical supply chain and drugs. 
Pharmacists and distributors should also upgrade their knowledge of current anti-counterfeit 
technologies. Pharmacists should take time to check products supplied to ensure they are 
authentic.  
Findings from primary data recommended that border controls should be strict to minimize the 
smuggling of counterfeit drugs into the system. Though the majority of respondents agreed 
that the implementation of proper supply chain management will help reduce the supply of 
counterfeit drugs and control the issue of stock out, laws need to be effective for the successful 
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Interview Questions for  pharmacist  
1. How long have you been practicing as a pharmacist?  
2. How long have you owned or managed your pharmacy?  
3. Do you know about supply chain management?  
4. In your opinion, will supply chain management reduce the penetration of counterfeit 
drugs into Nigeria’s pharmaceutical supply chain? 
5. How do you select your distributors? Are there specific requirements that influence your 
choice of selecting a distributor? 
6. How is the warehouse or storeroom secured? Is personnel access properly defined? 
7. Have you ever experienced a stock out? What is the cause? How did you handle the 
situation? 
8. Do you have a defined structure to guarantee the authenticity of products supplied?( 
explanations: Aside from checking the supply of drugs to confirm if the products 
delivered corresponds with your order, do you check to confirm if they are genuine?)  
9. Do you agree that as a pharmacist you play a vital role in reducing the spread of 
counterfeit drugs in Nigeria? 
10. Are you aware of any pharmaceutical distribution laws? 
11. What do you think is the reason why the implementation of regulations and laws suffer 
poor implementation? 
12. Have you ever been supplied counterfeit drugs? 
a. What aids the distribution of counterfeit drugs? 
13. Are you aware of any anti-counterfeiting technologies, if yes do you think they will help 
in the spread of counterfeit drugs in Nigeria? 
14. In your opinion should the penalties for counterfeiters be Reviewed. 
15. Do you have any recommendations or suggestions on how the distribution of 




Interview Questions for Distributors  
1. How long have you been a pharmaceutical Distributor?  
2. What is the procedure for becoming a distributor? Do you need a license to become a 
distributor? 
3.  How will you describe the pharmaceutical supply chain, what are the drivers that aid 
the supply of counterfeit drugs? 
4. How do procure your drugs? Do you distribute for a home-based pharmaceutical or an 
international pharmaceutical company? or a combination both? 
5. In your opinion, do you think the procedure for drug procurement should be broken 
down? 
6. Roughly how many pharmaceutical companies do you distribute for? 
7. Roughly how many pharmacies do you distribute to? 
8. How do you manage multiple distributions? 
9. Do you validate how genuine the products are before distribution?  
10. Are you aware of any laws or regulations concerning pharmaceutical distributions in 
Nigeria? 
a. What do you think is the reason why the implementation of regulations or laws 
in Nigeria is poor? 
11. From research, it has shown that in Nigeria shortage of supply is an avenue which 
counterfeiters take advantage of? What is the cause of a shortage of supply? And How 
often do you experience out of stock? 
12. Research has shown that the multiple intermediaries (people) in the pharmaceutical 
supply chain facilitates the supply of counterfeit drugs to pharmacies in Nigeria? Do you 
agree? 
13. Do you think the penalty for counterfeiters should be reviewed? 
14. Are you aware of any anti-counterfeit technology that will be useful in reducing the 




15. From your years of experience do you have any suggestions or recommendations on 
how the supply chain can be improved to reduce the loopholes which facilitate the 
supply of counterfeit drugs? 


















































INTERVIEW FINDINGS FROM PHARMACIST  
Knowledge of supply chain management 
All participants knew supply chain management except one participant who has very 
little knowledge of it. The majority of participants learned from school and one 
participant learned from journals and newsletters.  
In response to supply chain management as a solution to reducing the infiltration of 
counterfeit drugs into the Nigerian Pharmaceutical Supply Chain 
Participant 1: “From my own experience I would say No, it can't. Within the Nigerian 
market, I don't think supply chain management can quell the bane of counterfeit drugs. 
The reason is that in the Nigerian market, there are players whose entire business is built 
on the production and sale of counterfeit drugs and they are people who even seek them 
out and buy from them to make more money. We have a corrupt system in place here 
which thrives on such practices, and the lack of strong regulation and implementation of 
laws are already grounds that allow for these fraudsters to thrive and prosper. These 
fraudsters know how to work around NDLEA, SON, and NAFDAC”. 
Participant 2: “Yes, it will help reduce the spread of counterfeit drugs, because currently 
the agency in charge of counterfeit drugs in Nigeria is facing a lot of challenges, majorly 
logistics problem which makes it difficult to get rid of counterfeit drugs.” 
Participant 3: “Yes, it can by ensuring that batches are tracked and traced from the point 
of the manufacturer to the end-user. So that in a situation where there is a problem 
along the way the products can be easily traced. If NAFDAC effectively applies supply 
chain management, it will go a long way in reducing the spread of counterfeit drugs”. 
Participant 4: “Yes, if managed properly it will be effective in reducing the spread of 
counterfeit drugs”.  
Participant 5: “Yes, if pharmacies purchase drugs from regulated and licensed stores, 
instead of open markets”.  
Participant 6: “Yes, it can if properly monitored, but if not properly monitored it will be 
difficult to be used in Nigeria. Many parties involved in the supply chain are not sincere 






Participant 7: “Yes it will reduce the spread of counterfeit drugs, though the awareness is 
still coming up in Nigeria it will help with proper monitoring of the supply chain”.  
Response to characteristics which influence the selection of distributors 
Participants 1 & 5 select distributors based on integrity, recommendations, and referrals 
and their track record in the industry.  
Participants 3&4 Use pharmaceutical representatives, distributors who have direct links 
with the companies.  
Participants 2 & 7 Consider the price of the distributor, the quality of products, and the 
distributors who distribute known brands. Participant 7 also added that the location of 
the distributor is also for the company.  
Participant 6: The distributor must be a licensed professional and have a NAFDAC 
registration number and be permitted to distribute.  
Response to the security of storerooms and how stock out is handled  
All participants responded to personnel access been strict and properly secured. Most 
participants mentioned that only one person has access to the storeroom. Participant 3 
mentioned only the manager and the storekeeper have access to the storeroom. 
In response to how an out of stock situation is handled, most participants stated that 
they wait for the distributor to supply the product the because if one licensed 
distributor does not have the possibility of another licensed distributor have is slim. 
Furthermore, two participants attributed stock out to High demand and low supply or 
transport delays from distributors. 4 participants out of the 7 stated they recommend 
other brands to consumers that have the same effect.  
Participant 5 also added that “when there is stock out some dubious people even 
wholesalers go to China and duplicate the packs of these drugs, make something else, 
write on the body and supply. And because it is in high demand, people don’t look at 






Response to how they guarantee the authenticity of products supplied. 
Participant 1: “For multinational companies, I check if the security features like 
holograms, MAS are present, but for companies that don’t have these features, I just 
trust the distributor”. 
Participant 2: “Uses the MAS feature to check and sometimes confirms with NAFDAC” 
Participant 3: “Uses the MAS feature and checks for NAFDAC registration number” 
Participant 4: “Uses the Batch Number, Stock ID and confirms with the company” 
Participant 5: “Relies on the credibility of the Distributor” 
Participant 6: “Checks for NAFDAC registration number, confirms with the company, and 
trust the distributor”.  
Participant 7: “Checks the packaging of the product and checks the seal of the product”.  
Response to the role of pharmacists in reducing the spread of counterfeit drugs in Nigeria 
All participants agreed that they play a vital role in minimizing the spread of counterfeit 
drugs.  
Participant 1: Highlighted that it’s an issue of integrity and as pharmacists, it’s important 
to take any complaint from a customer very seriously. Also, as a pharmacist, it is 
important I buy products from the right source no matter the markup and report any 
form of counterfeit drugs as either reported by a customer or noticed as a pharmacist.  
Participant 2:  stated that amongst all the medical professions, pharmacists hold the 
highest responsibility in minimizing the spread of counterfeit drugs.  
Participant 3: “Educate clients on how to buy drugs from registered pharmacies and not 
drug markets”.  
Participant 4: “check the products to confirm the authenticity of the product before 
dispensing it to patients and follow up on patient feedback”. 
Participant 5: “Advice and counsel patients on the right point of purchase. But the open 
markets must be shut down, because as long as there are open there is very little we as 
pharmacists can do because people will still purchase drugs from there which is 
detrimental to their health, hence the urgent need for the government to do something 





Participant 6: “By selecting the right distributors and cross-checking products before 
dispensing them to patients” 
Participant 7: “By checking products to confirm their NAFDAC numbers, quarantine 
suspicious batches and start a follow-up investigation on the batch and communicate 
suspicious batch number to colleagues”  
 
Knowledge of pharmaceutical distribution laws and response to why laws are poorly 
implemented 
5 participants admitted to knowing distribution laws, while 2 participants were not 
familiar with any laws, but they all responded to why laws are poorly implemented.  
Participant 1: the poor implementation of laws is because of the relaxed culture in 
Nigeria, no one takes anything seriously, hence culprits get away with such a great 
offense as drug counterfeiting.  
Participant 2: “laws are poorly implemented because everything has been politicized” 
Participant 3: “corruption has eaten deep, hence the regulatory body in charge is more 
concerned with allowing anyone to practice whether they are qualified or not, as long as 
they can sort them out. Unfortunately, they are more non-pharmacist in the business 
than licensed pharmacists”.   
Participant 4: “poor implementation is because the chain is wide, a lot of sectors are 
involved in the process and government is not making enough effort to ensure these 
laws effectively implemented”.  
Participant 5: “Laws have been poorly implemented because of greed and corruption in 
the system” 
Participant 6: “laws are poorly implemented because they are no strict regulations in the 
system and greed and corruption have taken over the day”. 
Participant 7: “laws are not properly implemented because the regulatory bodies in 
charge are not making enough effort for these laws to be implemented and the 





Response to experience with been supplied counterfeit drugs and what aids the 
distribution of counterfeit drugs.  
All participants have not been supplied with counterfeit drugs. They all had similar views 
on what aids the distribution of counterfeit drugs, but they all stated that as long as you 
buy from the right source the possibility of been supplied counterfeit drugs is minimal, 
“it is impossible” as one of the participants said.  
All participants mentioned that the major cause of counterfeit drugs in Nigeria is the 
open markets. If pharmacists or distributors don’t buy from the open markets, the 
spread of counterfeit drugs will reduce, although some people are specifically in this 
business for the profit, hence some pharmacists buy only from the open markets 
without caring about the consequences on the consumers”. Some participants also 
added greed, corruption, and poverty to the factors which aid the distribution of 
counterfeit drugs and participant 2,3,6 &7 also added the poor implementation of laws 
and relaxed behavior from regulatory bodies.    
Knowledge of anti-counterfeit technology, and response to how it will help reduce the 
spread of counterfeit drugs 
5 participants were familiar with anti-counterfeit technologies, all 5 were familiar with 
MAS while participant 1 is also familiar with Holograms and tamper seals, while 
participant 5 is also familiar with RFID. 2 participants were not familiar with anti-
counterfeit technologies.  
According to participant 1, “these anti-counterfeit technologies have been useful in fighting the 
spread of counterfeit drugs but not in a widespread manner. This is because these technologies 
are expensive and companies are trying to cut down cost, but companies which use these 
technologies use them to protect their products from counterfeiting”.  Participant 2 highlighted 
that the “MAS technology has not sufficiently helped because the response time is slow, and 
sometimes it takes up to 3 days to receive a response and sometimes consumers receive false 
replies, genuine drugs are tagged as fake and vice versa. MAS has not been efficient enough. He 
also stated the more anti-counterfeit technologies should be deployed because the MAS 






dubbed by counterfeiters too”.  Participant 3 stated that “MAS technology has helped 
cut down the spread of counterfeit drugs but not enough. More enlightening needs to be 
done because many people are not aware of it. He also advised new technologies should 
be introduced”. Participant 5 mentioned that “the MAS technology has not been 
effective enough because not all drugs have the feature and consumers need to be 
educated more on the anti-counterfeit technology. Participant 7 stated, “that the 
effective use of anti-counterfeit technologies will help reduce the spread of counterfeit 
drugs”.  
Response to reviewing the penalties for counterfeiters 
All participants agreed that the penalty for counterfeiters should be reviewed, not just 
reviewed but strongly implemented when reviewed. Two participants likened it to 
murder and recommended all culprits should be given a death sentence and one 
participant recommended life in imprisonment. Other participants strongly 
recommended a review is overdue.   
Recommendations and suggestions 
Participant 1: “As a country, we should strengthen our supply chain system to reduce the 
event of stock-outs which gives room for these fraudsters. But what we need is for more 
companies in Nigeria to invest in security features for their original drugs with subsidies 
from the government. These companies should properly advertise and educate the 
populace on the presence of these security features so that they are more armed with 
information that can help them identify the fakes when they make their purchases. 
When I worked for GSK as a Medical Representative marketing Augmentin, we were 
trained on how to let our customers know about the security features on the drug. At 
Onitsha head bridge, they had 4 different grades of the same Augmentin we were 
marketing, all fake. We had to do a lot of work to expose their shady practices and make 
sure that our customers could tell the difference. It’s a lot of work but someone has to do 
it and it falls on the Nigerian government through its regulatory bodies and the 





Participant 2: “There should be a central distribution point for all drugs and all open 
markets should be shut down. The central distribution should be monitored and 
controlled by professionals, by pharmacists who understand the pharmaceutical 
distribution network, this is one-way the distribution of counterfeit drugs can be reduced 
in the system”.  
Participant 3: “The Pharmaceutical Council of Nigeria should ensure only registered 
pharmacists are allowed to sell drugs and handle all drug-related matters because 
unfortunately, corruption has affected the system whereby lame-men, men who are out 
to make money are allowed to be part of the system”.  
Participant 4: “All necessary regulatory bodies should do more, and all health 
professionals should be involved in the fight against counterfeit drugs. Furthermore, the 
government should ensure the movement of drugs are followed properly and consumers 
should be careful where they purchase drugs from and also confirm the authenticity of 
the product before using it”. 
Participant 5: “More drugs should carry the MAS features, the government should 
strengthen our regulatory bodies, pharmacists should support pharmacists, consumers 
should be properly educated on the importance of purchasing drugs from proper 
pharmacies and if possible corruption should be removed from the system”  
Participant 6: “Laws guiding the border should be implemented effectively and the 
Importation and exportation of drugs should be properly monitored. All companies 
exporting drugs into Nigeria should be thoroughly cross-checked and all duly registered 
with NAFDAC”.  
Participant 7: “Drugs should not be purchased from open markets, because drugs bought 
from the right source reduces the spread of counterfeit drugs”.  
INTERVIEW FINDINGS FROM DISTRIBUTORS 
All distributors who participated in the interview process have been in the business for more 
than 5 years. 4 participants responded via phone interview while two responded via text.   





According to all participants, you have to get a license and be registered with the 
pharmaceutical council Of Nigeria (PCN) before you can start anything, after getting 
your license then you procure your pharmaceutical premise and ensure the required 
distance between each premises is adhered to as per FMoH standard. There must be a 
pharmacist on ground just in case anything goes wrong. Then the ministry of health 
officials will come and inspect to ensure everything is done according to the stated 
requirement. This inspection is carried out three times before you are finally approved 
to distribute drugs. Participant 1 also added that the procedure of becoming a 
distributor has been evolving since she became a distributor in 2000, and every year 
your premise council license is taken for revalidation. Participant 3 added you will need 
to secure another license if you intend to be importing drugs into the country.  
Response to describing the pharmaceutical supply chain 
Participant 1: “the pharmaceutical supply chain is evolving, it keeps evolving” 
Participant 2: “at this point, I will say the pharmaceutical supply chain is perfect because 
everyone in the system is advancing, but sometimes we face logistics problems which 
cause a delay in supply of goods” 
Participant 3: “it’s relatively fair, with the coming of marketing companies (also known 
as national distributors) such as Worldwide Commercial Ventures (WWCV) and “ Assene-
Laborex”, these companies have introduced a different distribution pattern by act as an 
intermediary between the manufacturing companies and the distributors”.   
Participant 4: “there is not much control over the pharmaceutical supply chain because a 
lot of unskilled and untrained people have been allowed into the system which has 
tampered with the integrity of the system. Ones you have the money the regulatory body 
in charge gives you license to start, and most of these people do not care about the 
health of the patients, they are more concerned about the profit they will make”. 
Participant 5: “It is more specialized than consumer goods or commodity chains, thus requires 
regulation and skilled handlers in health logistics and regulatory and quality management. From 
the distribution angle, up till recently lots of the major players in the sector, have either been 





inexperienced, or unrelated skills. A problem aided by a weak regulatory structure that 
has left the regulatory controls to the ethical discretion of the pharmacists in production, 
distribution, or retail. For example, the National Drug Distribution Policy 2012 is still 
unimplemented to date”. 
Participant 6: “The chain is disorganized, and the presence of the open-drug market 
drives the counterfeiting industry” 
Response to the procedure of drug procurement and If the procedure should be broken 
down.  
In response to drug procurement, all the participants mentioned they procure their 
drugs from these national distributors (WWCV and Assene-Laborex ) because these 
companies have the right to majority of the international drugs been sold in Nigeria. 
Participant 1 highlighted that for other manufactures within the country such as Emzor, 
Farmatech, etc. you will have to go and meet them with your license to show interest 
and if they do their background check, if you have clean records then you become a 
distributor. Participant 3 & 6 mentioned they purchase some products from open 
markets as well from specific distributors, Participant 4 said he imports some of his 
drugs, and Participant 5 mentioned he procures some of his drugs from the public 
health distribution system.  They all responded that more people need to be part of the 
procurement system but at the same time it needs to be improved.  
Response to distribution log and how they manage multiple distributions 
All participants highlighted that they distribute to a lot of companies ranging from 20 
and above which includes both hospitals and pharmacies. All participants highlighted 
that pharmacies they distribute to have a logbook with them, and most time the 
pharmacies are the ones who come to pick-up the product. For every delivery or pickup, 
each pharmacy sign in the distributor log and the staff on ground from the distributors' 
side signs to prove they were the ones who handled the transaction process. As for 
Hospitals, they go with logbooks, the storekeeper signs, and delivery officers’ signs as 
well.   







Participant 2 mentioned they check the expiration dates before distribution and confirm 
the batch numbers as well. Participant 3 mentioned they check if the seal is in order 
before signing the letter that comes with the delivery. Participant 1 &4 highlighted they 
trust the source where they purchase drugs from, so they don’t check. Participant 5 &6 
responded yes to checking the products before distribution.  
 
 
Knowledge of pharmaceutical distribution laws and response to why laws are poorly 
implemented 
Participant 1: “I told you that there’s a law, say that if you want to be a national 
distributor you’ve got to have warehouses in the six geo-political zones of Nigeria.so 
there is a law, there is a pharmaceutical distribution bill. So, there is a law. I wouldn’t say 
that implementation is poor, I would say that the law was made it has made it difficult 
for people to enter easily, because of all the infrastructure you have to put in place, if 
they are not implementing it we would have more than two distributors. Do you get 
what I’m saying, if they are not implementing it everybody would be doing it, they are 
implementing, they are searching, they are checking, that’s why we only have two that 
have the financial strength, doing it. And, indeed, the open market is still operating, it 
indeed is an ill in our society, for how many now, I’ve been a pharmacist for how many 
years’ now, since 1992 that’s 28 years that has been the story, you know, complain 
about the open market and nobody has an answer, to how the open market would stop. 
I don’t know maybe somebody would come and they would be wisdom for the person to 
stop the operation of these open markets, but right now there isn’t any like that, hence 
the open market is still operating. We as professionals should look inward and stop 
blaming people for our woes, you know let us all decide if we do not want open market 
do not register them when they apply for registration, as simple as ABC. That’s all, but 






Participant 2: “Well the challenge there is that it has been implemented but people tend 
to break them, that is why there is a lot of drug trafficking in the world, but people tend 
to break these rules for their selfish interest”. 
Participant 3: “corruption and those in government are not doing their job” 
Participant 4: “the laws are static, the regulatory body in charge has the stipulation of 
what should be done but the implementation is poor. This can be further attributed to 
the fact that 50-70 percent of people distributing drugs are not pharmacist” 
Participant 5: Yes, “poor implementation is as a result of Low level of workforce and 
motivation/support for the regulators from the government. Knowledge and awareness 
of consumers (MAS – mobile authentication system used for example) Institutional and 
systemic corruption could also play a big role as the drive to make money at the expense 
of ethics could be overwhelming on the system. Deregulated distribution channels, e.g. 
Nigeria host the largest open drug markets in West Africa, or probably Africa, these have 
over the years rivaled the relatively organized distribution channels. They also enjoy 
support (indirect) from multinational pharmaceuticals who compete for profit”. 
Participant 6: “Corruption & lack of political will on the part of the government”. 
Response to how often out stock is experienced and the cause of our stock and how it is 
handled.  
All participants responded to experiencing out of stock regularly.  
Participant 1: “you always have, you will be out of stock and you’ll restock again, and 
you will be out of stock, as I said these national distributors they keep on changing laws. 
For example, you’ve placed in your order and normally they say they will collect 
postdated cheque form you that will clear in a month and then before the end of the 
month your stock finishes, you say I need stock they tell you to pay up for the last one, 
the check is in their hand though, but no goods till the previous cheque has been 
cleared”.  
Participant 2: “when there is a high demand for a product but low supply, sometimes its due to 
scarcity of the product in the market which makes the price go up and because of that we tend 





moment to give our customers and sometimes if it’s a foreign drug that is not produced 
in Nigeria it could be because it has not been cleared by the customs”. 
Participant 3: “scarcity could be caused by raw material scarcity or government policy on 
a particular product and greed. During scarcity, we opt for alternative brands or a 
verified alternative supplier from another company. “During the out of stock period 
some counterfeiters quickly take advantage of the period, send a sample of the scarce 
product to countries like China and quickly dup the packing, the batch number, and other 
features similar to the product and bring it back into Nigeria and sell”. 
Participant 4: “we experience out of stock regularly because of delay in transportation 
and upsurge in a particular disease. Sometimes we look for an alternative brand, but 
when it’s a rare drug we wait till its available, this is where counterfeiters take 
advantage of”.  
Participant 5: “Inaccurate demand forecast, limited production capacity, logistics factors, 
or related reasons. Rather the counterfeiters benefit from the lower production costs (of 
producing counterfeits) and have eroded the original manufacturers of the profits and 
incentives to expand their markets.” 
Participant 6: “it is caused by the low production capacity of pharmaceutical 
companies.” 
Response to the number of people involved in the pharmaceutical distribution chain. 
Participant 1: “I don’t think we are even enough. if the national distributors are many, it 
will allow distributors to order drugs even before the next cheque is due, but because 
they are only two in Nigeria, we have to follow their rules” 
Participant 2: “Yes they are a lot of people involved in the supply chain, and it’s helping 
the supply chain.” 
Participant 3: “ the Nigerian market is large and due to corrupt government people who 
don’t have any business been distributors are given the license to supply drugs”  
Participant 4: “the people involved in the supply chain are not enough because the rural 





Participant 5 fairly agreed while participant 6 responded yes, they did not give any 
further explanation after this considering they responded via text.  
 
Knowledge of anti-counterfeit technology, and response to how it will help reduce the 
spread of counterfeit drugs  
Participant 1: “Yes, the MAS technology and hologram. For the hologram I think anybody 
can create the hologram, for the mobile authentication, I think it needs a little bit more 
work, there was one incident about a drug that I bought from WWCV, a GSK product and 
then somebody scratched it and the numbers were supposed to be ten but on that paper, 
they were nine, so the person sent and of course they would say it is fake because the 
numbers are incomplete. When the customer called the number, the official responded 
rudely, but when I called the official responded properly and confirm the drug was 
genuine”.  
Participant 2: “the MAS technology and checking the batch number of products 
produced. These technologies have been useful in reducing the threat of counterfeit 
drugs and the use of sale representative has also helped reduce the infiltration of 
counterfeit drugs into the system”  
Participant 3: “NAFDAC registration number. It has been effective in differentiating 
authentic products from fake products”  
Participant 4: “No” 
Participant 5&6 responded yes to the knowledge of anti-counterfeit technology.  
Response to reviewing the penalties for counterfeiters 
All participants stated that the penalties for counterfeiters should be reviewed and not 
just reviewed implemented effectively.  
Recommendation and suggestions  
Participant 1: “right now as it is, I would say they should leave it as it is now, although as 
I said we are evolving when people get tired, more people will find a way to raise money 
and there would have many more national distributors, and then I think it should be 






Participant 2: “I believe the pharmaceutical supply chain can be improved through the 
use of maybe internet services, you can order online, rather than writing paper snapping 
and sending, or there should be an app or software whereby you just click and it makes it 
easier for you to order”. 
Participant 3: “the presence of national distributors have improved the drug distribution 
system in Nigeria. I will encourage that more national distributors should come in 
because the act as a mediator between the manufacturing companies and the 
distributors. Patent stores should only sell what they are approved to sell. Furthermore, 
the routes in which drugs come into Nigeria should be checked. NAFDAC officials should 
be placed at all borders to inspect pharmaceutical products coming into the country”.    
Participant 4: “the distribution of drugs should be left strictly to professionals, those who 
are interested in the wellbeing of patients and not those who out to make profit. 
Constant monitoring should be done within the industry and a regulatory body to 
specifically monitor drug crimes should be inaugurated under NAFDAC”. 
Participant 5: “If the distribution is better strengthened and structured, the open market 
systems can be easily phased out. Employ new technologies, e.g. blockchain has a 
promising prospect in helping to track end to end distribution of medicines. 
IOTs (internet of things) such as real-time tracking systems as well can improve chain 
visibility”. 
Participant 6: “Registered Pharmacists & pharmacies, should be fully & wholly involved & 
made to man all drug distribution channels to aid tracking of drugs from the production 
level to consumption and all open drug markets must be closed down forthwith”.   
 
